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ABSTRACT
One of the major complication of hypothyroidism is atherosclerosis and
cardiovascular disease. Hyperhomocysteinemia is an important and
independent risk factor for atherosclerosis. Hypothyroidism decreases hepatic
levels of enzymes which converts homocysteine to methionine that leads to
increase in homocysteine level in the circulation of hypothyroid individuals.
The aim of the study was to assess fasting total plasma homocysteine level in
recently diagnosed hypothyroidism. The study included thirty  recently
diagnosed hypothyroid individuals, thirty treated hypothyroidism and thirty
apparently healthy subjects  with age and sex matched. The study group was
selected after obtaining ethical committee clearance and  consent from
subjects attending outpatient department of Endocrinology, Madras Medical
College, Chennai. Thyroid profile, homocysteine and lipid profile were
measured in fasting blood samples. Total plasma homocysteine levels was
significantly more in recently diagnosed hypothyroidism compared to controls
and treated hypothyroidism with p value 0.006. By this study we confirmed
hyperhomocysteinemia in hypothyroidism which may lead to atherosclerosis.
Hypothyroidism is one of the treatable cause for hyperhomocysteinemia.
Lipid profile was altered in recently diagnosed hypothyroidism. Total
cholesterol, triglycerides, LDL cholesterol and HDL cholesterol were high in
recently diagnosed hypothyroidism compared to controls and treated
hypothyroidism. Lipid profile was highly significant between the study
groups with the p value <0.001 except HDL cholesterol. During treatment
with thyroxine hypothyroid patients should be monitored for lipid profile,
total plasma homocysteine levels. In hypothyroidism estimation of total
plasma homocysteine level is may be used as screening test to identify and
monitor cardiovascular risk.
Keywords : Hypothyroidism, Homocysteine, Lipid profile
1INTRODUCTION
Thyroid diseases are common worldwide. In India too, thyroid
diseases are more prevalent. Thyroid disorders are the most common
among all the endocrine diseases[1]. In pregnancy thyroid diseases are the
second most common endocrine disease and its prevalence is 0.3-0.5 %[2].
Approximately 42 million people are affected by thyroid diseases.
In India 11 % of the population are affected from hypothyroidism.
Among these 12 % of adults have palpable goiter, 16.7 % of adults have
anti-thyroid peroxidase and 12.1 % have anti-thyroglobulin antibodies.
The older population were affected more than the younger population.
Women were three times more prone for hypothyroidism than men[3].
Hypothyroidism [myxoedema] was first described by Thomas
Curling in 1850. Thyroidectomy was first performed in 1880. Anti-
thyroid drugs and radio-iodine therapy were developed in early 1940’s [4].
Homocysteine is a sulphur containing amino acid which is formed
as an intermediate in the methionine metabolism and methionine is the
only source of homocysteine in the human body.
Homocysteine undergoes auto-oxidation and produces hydrogen
peroxide which is a free radical. Glutathione peroxidase prevents
oxidative degradation of nitric oxide[5]. Among thiol containing
2aminoacids homocysteine has unique property to inhibit glutathione
peroxidase [5]. Hyperhomocysteinemia destroys glutathione peroxidase,
decreases its intracellular concentration and increases oxidative
degradation of nitric oxide, thereby decreasing its bioavailability.
Damage to endothelial cell disrupts the normal function of endothelium
resulting in leukocyte and platelet adhesion, thrombosis, smooth muscle
proliferation, lipid accumulation and finally atheroma [6,7,8].
Hyperhomocysteinemia is defined as the levels of homocysteine >
10 ?mol/L. There are various causes for hyperhomocysteinemia.
Hypothyroidism is one of the treatable cause for hyperhomocysteinemia.
For each 1 ?mol/L increase in homocysteine concentration there is a 1 %
increase in risk to develop cardiovascular events or death [9].
Hyperhomocysteinemia is an important and independent risk factor
for atherosclerosis. 60% of the patients affected by cardiovascular disease
have hyperhomocysteinemia[10]. Many studies have reported mild
hyperhomocysteinemia as an independent risk factor for venous and
arterial occlusive disease [11,12,13].
AIM OF THE STUDY
3AIM OF THE STUDY
Hypothyroidism is the most common endocrine problem in recent
years, more prevalent in India and about 11 % of population[3] were
affected. Almost 1 in every 10 person are affected with hypothyroidism.
Overt hypothyroidism has been found to be associated with
cardiovascular disease. 60% of the patients affected by cardiovascular
disease have hyperhomocysteinemia[10]. Thyroid dysfunction has adverse
role in nearly all major metabolic pathways like carbohydrate, protein and
lipids.
In hypothyroidism common metabolic abnormalities are
dyslipidemia, hyperhomocysteinemia and Insulin resistance.
Hyperhomocysteinemia causes oxidative stress to the cell, increase
production of reactive oxygen species and leads to complications.
Homocysteine has been identified as an independent risk factor for
atherosclerosis. Patients with unexplained hyperhomocysteinemia should
be screened for thyroid status[14]. Hypothyroidism is one of the treatable
cause for hyperhomocysteinemia.
4Objectives:
1.  Estimation of Total Plasma Homocysteine level in recently
diagnosed hypothyroid individuals and to compare them with the
lipid profile in the same group.
2.  To compare the levels of homocysteine and lipid profile between
recently diagnosed hypothyroid cases and apparently normal
individuals.
3.  To compare the homocysteine levels and lipid profile between
recently diagnosed hypothyroid cases and treated hypothyroid
patients.
4.  To compare the homocysteine levels and lipid profile between
treated hypothyroid patients with apparently normal individuals.
5.  To correlate TSH level with lipid profile and homocysteine levels
in all the above groups.
REVIEW OF LITERATURE
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Thyroid gland Anatomy and Embryology :
The word Thyroid is derived from the Greek word [thyreos-shield],
situated anterior to the trachea between cricoid cartilage and suprasternal
notch[15]. It has two lobes joined by an isthmus. It is composed of many
spherical follicles made up of follicular cells which synthesize
thyroglobulin. In the center of the follicle, is the lacuna filled with
secreted colloid proteineous fluid containing predominantly
thyroglobulin. The follicular cells becomes columnar when it is active
and cuboidal when it is inactive[12].
     Thyroid gland is an important endocrine gland which develops at
the 24th day of intrauterine life from an anterior out pouching of the
foregut, and then it descends along with thyroglossal duct to reach its
location by 7 weeks of gestation. At about 20 weeks the fetus starts
producing thyroid hormones due to maturation of hypothalamic-pituitary-
thyroid axis[18].The thyroid medullary C cells which produces calcitonin –
a calcium lowering hormone develops from ultimobranchial body, a
derivative of neural crest[15].
6Thyroid hormone synthesis:
Thyroglobulin is the precursor of thyroid hormones, which is
synthesized from the rough endoplasmic reticulum of the follicular cell.
Thyroglobulin is a glycoprotein homodimer of 660 kDa. It consists of
2769 amino acids, including 134 tyrosine residues . Among these only 25
– 30 residues are iodinated. Principal stimulator of thyroglobulin
synthesis is TSH[18].
7Thyroid hormone synthesis :
Iodide trapping
Organification of Iodine
Iodination of Thyroglobulin
Coupling reaction [MIT + DIT and DIT + DIT ]
Release of hormones
Iodide trapping:
Recommended dietary allowance of iodine is 150 microgram /
day[11].
In thyroid hormone synthesis, iodide uptake is the first critical step
which is mainly derived from the diet. Ingested iodine is absorbed and
bound to albumin in the circulation. Unbound iodine is excreted through
FIGURE 1 : THYROID HORMONE SYNTHESIS
Courtesy : Guyton and Hall. Textbook of Medical Physiology [12 th edition]
Calibrators :
CALIBRATORS CONCENTRATION
Calibrator 1 2 ?mol/L
Calibrator 2 4 ?mol/L
Calibrator 3 8 ?mol/L
Calibrator 4 15 ?mol/L
Calibrator 5 30 ?mol/L
Calibrator 6 50 ?mol/L
HOMOCYSTEINE STANDARD
CONCENTRATION
ABSORBANCE
50 ?mol/L 0.2443
30 ?mol/L 0.3447
15 ?mol/L 0.4887
8 ?mol/L 0.8004
4 ?mol/L 1.1251
2 ?mol/L 1.3059
8kidney. Iodide is transported to the follicular cells by active transport via
sodium-iodide symporter [NIS]. Sodium-Iodide symporter is encoded by
the gene SLC5A5. It is a glycoprotein which has 643 aminoacids [12]. The
iodine concentration in the follicular cells is 30-40 times greater than the
circulation[18].
Na+/I- symporter is present in the basolateral surface of the
follicular cells, highly expressed in the thyroid gland and low in salivary
glands, placenta, lactating mammary gland[15].The iodide transport
mechanism is highly regulated by dietary supply of iodine. Low iodine
intake increases the expression of NIS and stimulates the uptake.
Whereas high intake suppress NIS [15]. Iodide is transported in to the
lacuna by another transporter pendrin situated on apical surface of the
follicular cell. It is a glycoprotein encoded by the gene SLC26A4[12].
Pendrin[Chloride / iodide antiporter] is a passive iodide transporting
glycoprotein also present in kidney and inner ear[12,16].
Organification of Iodine:
Iodide after entering in to the lacuna gets oxidized to iodine by an
enzyme thyroid peroxidase which is a heme containing protein. In this
reaction hydrogen peroxide acts as an electron acceptor, and generates
9reactive iodine. Hydrogen peroxide is produced at the apical membrane
by the action of DUOX 1 and 2 [Dual oxidase][12].
Iodination of Thyroglobulin :
The reactive iodine atom is added to the selected tyrosine residues
in the thyroglobulin to produce either monoiodotyrosine or
diiodotyrosine. This reaction is catalyzed by thyroperoxidase.
Coupling reaction:
The coupling reaction is catalyzed by thyroperoxidase enzyme to
produce either triiodo / tetraiodothyronine. T3 is formed by transfer of one
monoiodinated phenolic group from MIT to one DIT residue. T4 is
formed from two DIT residues with the transfer of one di-iodinated
phenolic group to another DIT residue[18]. These T3 and T4 are bound to
thyroglobulin and acts as a reservoir of thyroid hormones in the colloid.
Release of Thyroid hormones:
The coupled thyroglobulin is taken back in to the follicular cell by
pinocytosis. This phagosome is endocytosed by primary lysosome and
fused to form secondary lysosome, in which Tg gets digested and T3 ,T4,
DIT ,MIT and amino acids are released. This lipophilic T3 and  T4
10
molecules exit from lysosome and by diffusion across the follicular cell
plasma membrane it enters into the thyroid capillaries[18].
In the follicular cell cytoplasm uncoupled MIT and DIT are
deiodinated by an enzyme dehalogenase and free iodine are recycled for
hormone synthesis[18].
Transport of thyroid hormones:
The major hormone secreted from thyroid gland is T4 which is 20
times more than that of T3. Both are bound to thyroxine-binding globulin,
transthyretin, and albumin. These plasma-binding proteins increase the
level of circulating hormones, alter the hormone delivery to the target
tissues, and delays the hormone clearance. Free thyroid hormone in
plasma is physiologically active. Only 0.03 % of total T4 and  0.3  %  of
total T3 is in the free form [12].
? Thyroid binding globulin:
? Thyroid hormones are bound to this protein which is present
in low concentration in the circulation and has a high affinity
for T3.
? Each TBG molecule has one iodothyronine binding site.
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TBG level is increased in [11]:
              Pregnancy
              Drugs: Estrogen pills
                  Clofibrate
TBG level is decreased in :
         Liver disease
         Drugs : Glucocorticoids
Androgens
Phenytoin [17,20]
Salicylates [19,20]
           Cancer chemotherapeutic agents – eg. Mitotane
? Transthyretin :
? Also called as Thyroxine-binding prealbumin
? Affinity for thyroid hormones is low.
? Albumin :
? Even though it has a low affinity for thyroid hormones
because of its high plasma concentration, albumin is a major
carrier protein for thyroid hormones[15].
? Binds about 10% of the thyroid hormones.
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Table - 1:  Effect of Alterations in the Concentrations of Thyroid
Hormone-Binding Proteins in the Plasma on Various Parameters of
Thyroid Function after Equilibrium Has Been Reached.
Condition
Concentrations
of Binding
Proteins
Total
Plasma
T3, T4,
RT3
Free
Plasma
T3, T4,
RT3
Plasma
TSH
Clinical State
Hyperthyroidism Normal High High Low Hyperthyroid
Hypothyroidism Normal Low Low High Hypothyroid
Estrogens,
methadone,
heroin, major
tranquilizers,
clofibrate
High High Normal Normal Euthyroid
Glucocorticoids,
androgens,
danazol,
asparaginase
Low Low Normal Normal Euthyroid
Courtesy : Ganong 12 th Edition
Table – 1 shows that the concentration of thyroid hormone binding
protein is unaffected by hypo/hyperthyroidism.
Steroids and drugs like Clofibrate, danazol affect this binding
protein concentration. Inspite of this, individuals may be in euthyroid
state because free thyroid hormone concentration is normal.
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Characteristics of thyroid hormones are as follows :
Table 2 : Characteristics of Circulating T4 and T3
Hormone Property T4 T3
Serum concentrations
Total hormone 8 g/dL 0.14 g/dL
Fraction of total hormone in the free form 0.02% 0.3%
Serum half-life 7 days 0.75 day
Fraction directly from the thyroid 100% 20%
Production rate, including peripheral conversion 90 g/d 32 g/d
Intracellular hormone fraction 20% 70%
Relative metabolic potency 0.3 1
Receptor binding 10–10M 10–11M
Courtesy : Harrison 18 th Edition
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Table 3 : Effects of some drugs on thyroid function
Courtesy: Tietz Textbook of clinical chemistry and molecular diagnostics fourth edition.
Metabolism of thyroid hormones:
T4 and  T3 are metabolized by the enzyme deiodinases. There are
three different deiodinases which are active in homodimeric forms. This
enzyme has selenocysteine in its active site which is the cause for its
catalytic activity[11].
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? Type 1 [D1] - present in thyroid, liver, kidney and anterior
pituitary gland.
? D1 – converts T4 to  T3 [5’ deiodination] or rT3 [5
deiodination]
? Thyroid hormone stimulates D1 gene transcription and its
activity
? Km for D1-T4 complex is 1000 times greater than D2 or D3
? Type  2  [D2] present in thyroid, brown adipose tissue, CNS,
anterior pituitary, heart, skeletal muscle and placenta.
? D2- converts T4 to T3
? Thyroid hormone suppress D2 gene expression
? Type 3 [D3] found in liver, CNS, endometrium and placenta.
? D3- converts T4 to rT3 [18]
13 % of circulating T3 is secreted by thyroid gland, while 87 % is
formed by deiodination of T4[11].
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? Some of the T3, T4 is further metabolized to deiodotyrosines and
conjugated in the liver to form glucuronides and sulfates. They are
excreted through bile[11].
Mechanism of action of thyroid hormone:
? Circulating thyroid hormones enter into the cells through passive
diffusion and certain transporters like MCT 8, MCT 10 and OATP
1C1. MCT 8 and 10 are expressed in many tissues. OATP 1C1 is
expressed mainly in the brain [20].
? Crosses the nuclear membrane and binds to the intranuclear thyroid
receptors.
? Thyroid receptors are members of the steroid hormone supergene
family.
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? T3 has 10-15 times more affinity than T4 for the receptor binding.
There are two forms of thyroid receptor - ? and ?. Their expression
differs in various tissues.
? The aporeceptors bind to corepressors that inhibit gene
transcription.
? After binding of thyroid hormones to the receptor, conformational
change occurs that dissociates corepressors and recruits co-
activators. TR has carboxy terminal ligand binding domain and
central DNA binding domain. This DNA binding domain binds to
thyroid response element, a specific DNA sequence in the
promoter region of the target genes.
? Usually receptors bind most commonly as heterodimers with
Retinoid X receptor or as homodimers.
? Depending upon the nature of the regulatory elements in the target
gene the activated receptor can either induce or inhibit gene
transcription.
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T3, T4 in blood
Enters cell
Binds to nuclear receptors
T3 has high affinity than T4
Conformational change
co-activators
      Co-repressors
Induce / Inhibit gene transcription
FIGURE 2 : MECHANISM OF THYROID HORMONE
Courtesy : Guyton and Hall. Textbook of Medical Physiology [12 th edition]
19
Regulation of thyroid hormone :
Hypothalamic – Pituitary –Thyroid axis is a classical example for
feedback control. This axis senses variation in the thyroid hormone
concentration in the circulation and regulates them.
Thyrotropin Releasing Hormone regulates TSH secretion :
Hypothalamus secretes thyrotropin releasing hormone[TRH] which
is a tripeptide – polyglutamyl-histidyl-proline-amide. It is secreted from
the median eminence of hypothalamus and reaches the pituitary via
hypothalamic-pituitary portal blood.
TRH bind to its receptor in thyrotroph membrane of the pituitary
and activates phospholipase C that converts phosphatidylinositol
diphosphate into inositol triphosphate and diacylglycerol which acts as a
second messenger [21]. Inositol triphosphate increases intracellular
calcium and stimulates Ca2+ -calmodulin dependent kinases.
Diacylglycerol stimulates protein kinase C. Both kinases phosphorylate
proteins and releases thyrotrophin from the pituitary thyrotroph cells. T3
in the hypothalamus inhibits pre-pro-TRH mRNA[21,22] and also blocks
ability of TRH to stimulate TSH release.
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Neuropeptides like leptin and ? melanocyte stimulating hormone
regulates pre-pro TRH synthesis by stimulating TRH promoter through
leptin receptor and melanocortin 4 receptor respectively. Fasting
decreases leptin secretion which may decrease TRH synthesis and
amplitude of pulsatile TSH release [21,23].
Thyrotropin/TSH regulates thyroid hormone secretion :
Thyroid stimulating hormone otherwise called thyrotropin, is a
glycoprotein secreted by thyrotrophs from the anteromedial portion of
adenohypophysis. It consists of ? and ? subunits. ?mong these ? subunits
are identical to other glycoprotein hormones like Leutinizing hormone,
Follicle stimulating hormone and Human chorionic gonadotrophin. Beta
subunit is unique for TSH.TRH increases transcription of both subunits
and post-translational modification of TSH.
TSH undergoes two types of variations. Such variations are
pulsatile and circadian variation. TSH is secreted in 1 – 2 hours interval
in pulsatile manner. This is decreased during fasting, after surgery and
during illness. TSH levels start to rise at about 9 pm, peaks at midnight
and declines during the day. Half-life of TSH is 60 minutes. Most part is
degraded by kidney and to a small extent by the liver.
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TSH binds to its receptor in the thyroid gland. TSH receptor is a G
protein coupled receptor with seven transmembrane domains spanning
the membrane. After binding of TSH to its receptor it activates adenyl
cyclase through G stimulatory and increases the intracellular cAMP
concentration and activates protein kinase that phosphorylates many
proteins.
TSH increases thyroid hormone secretion by :
? Increasing proteolysis of thyroglobulin stored in the colloid to
increase T3 and T4 concentration
? Increasing the activity of iodide pump and iodide trapping
? Increasing the iodination of tyrosine residues
? Increasing the secretory activity of follicular cells
? Increasing the number of cells and converting inactive cuboidal to
active columnar cells.
FIGURE 3 : REGULATION OF THYROID HORMONE
Courtesy : Camilla Pramfalle, Matteo Pedrelli, Paolo Parini. Role of thyroid
receptors ? in Lipid metabolism: BBA Molecular Basis of Disease. Volume
1812, issue 8, August 2011: 929-937.
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Thyroid hormone receptors :
? Thyroid hormone receptors are encoded by two genes – ? and ?.
By different splicing of mRNA various isoforms produced. There
are four thyroid hormone receptors namely ?1, ?2, ?1 and ?2.
? Each receptors has 3 domains: [21]
? Transactivation domain at amino terminus , to interact with
transcription factors.
? DNA binding domain binds to promoter region of DNA
known as Hormone Response Element.
? Ligand binding domain and dimerization domain at carboxy
terminus.
? DNA binding domain of all four receptors are very similar.
? ?2 has unique carboxy terminus and does not bind to T3.
? Isoforms differ in their tissue expression. All tissues express ?1, ?2,
?1 isoforms.  ?2 is present in developing ear, hypothalamus and
anterior pituitary.
? Thyroid receptor ? is the major receptor in the heart. It regulates
the contraction and relaxation of the heart and the heart rate.
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? ?1 is the major receptor in liver, plays an important role in lipid
metabolism [24].
? In  the  absence  of  thyroid  hormone,  receptors  binds  to  DNA  and
usually leading to transcriptional repression.
? After binding of the thyroid hormone to its receptor it induces
conformational change in the receptor and acts as a transcriptional
activator.
 Thyroid hormones which acts through TR?2 regulates  TSH  and
TRH production by feedback loop mechanism[15].
Decrease in thyroid hormone directly increases TSH production
from the pituitary or by the action of TRH from hypothalamus . Thyroid
hormones are the major regulator of TSH secretion. The feedback effect
of thyroid hormones are mainly on the pituitary.
Functions of thyroid hormones:
Generally thyroid hormone activates transcription of large number
of genes in almost all cells in the body. This increases the synthesis of
enzymes, transport proteins, structural proteins, etc. In overall it increases
the functional capacity of the cell. Also thyroid hormones have non-
genomic cellular actions that are independent of gene transcription
24
effects. These effects are explained in several tissues including pituitary,
heart and adipose tissue [25].
Thyroid hormone upregulates the expression of:
? Growth hormone
? Myelin basic protein
? Alpha-myosin heavy chain
? Sarcoplasmic reticulum calcium ATPase
Thyroid hormone downregulates the expression of :
? TSH beta chain
? Beta myosin heavy chain
The non-genomic thyroid hormone action is on Plasma membrane,
cytoplasm and some organelles . For example in mitochondria it has
effect on oxidative phosphorylation, regulation of ion channels, activation
of intracellular second messengers eg. cAMP, Protein kinase signaling
cascade[25].
Increase of cellular metabolic activity :
Basal metabolic rate- Defined as energy required by an awake
individual during physical, emotional and digestive rest. It is the
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minimum energy required to maintain life or sustain vital functions like
respiration, circulation, heart and brain function.
? Basal metabolic rate is regulated by thyroid hormones. When this
hormone secretion is increased , BMR increases upto 60-100 %
above the normal level [25].
? Thyroid hormones increase oxygen consumption by metabolically
active tissues in the body except brain, anterior pituitary, spleen,
lymph nodes, uterus and testis. This is known as calorigenic action
of thyroid hormones[11].
? Thyroid hormones increase active transport through cell
membrane. One of the ion channels that gets activated is Na+/K+
ATPase.  This  uses  energy  and  produces  heat.  This  is  one  of  the
mechanisms leading to increased metabolic rate.
Effects on growth:
? Effects are mainly seen in growing children.
? Enhances growth hormone action on tissues.
? In hypothyroidism rate of growth is retarded.
? In hyperthyroidism rate of growth is increased and epiphysis close
at an early age.
?  Promotes growth and development of the brain during fetal life.
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Effects on carbohydrate metabolism :
? Increases absorption of glucose from gastrointestinal tract.
? Rapid uptake of glucose by the cells
? Stimulate gluconeogenesis
? In hyperthyroidism plasma glucose level suddenly rises after a
carbohydrate meal and falls rapidly
Effects on Fat metabolism:
? Thyroid hormone increases lipolysis
? Stimulates Fatty acid oxidation
? Lowers plasma cholesterol and triglycerides level
? By increasing LDL receptors in the liver , resulting in excess
removal by hepatic tissue.
? By increasing cholesterol secretion in the bile and loss in
feces.
Effects on protein metabolism :
? At physiological concentration thyroid hormone increases protein
synthesis and also its degradation to some extent.
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? Thyroid hormone provides gluconeogenic substrate by protein
degradation mainly from the muscle which is exaggerated in
hyperthyroidism.
? Thyroid hormone increases hepatic levels of methionine synthase
or methyltetrahydrofolate-homocysteine methyl transferase
enzyme that methylates homocysteine to methionine which
maintains homocysteine concentration in the normal range.
Homocysteine
Methionine synthase
Methionine
Effects on Cardio Vascular System :
? Thyroxine has chronotropic and ionotropic effect on heart muscle.
? Increases blood volume by increasing cellular metabolism and
vasodilatation that leads to activation of Renin-Angiotensin-
Aldosterone system
? Increases cardiac output
? Increases heart rate
? It sensitizes heart to adrenaline
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Effects on Respiratory System :
Increases respiratory rate and depth of respiration due to increased
utilization of O2 and formation of CO2.
Effects on Gastro Intestinal Tract :
Increases appetite and gastrointestinal motility
Effects on Central Nervous System :
? Increases the activity of brain
? Thyroid hormone is necessary for brain development.
? From the circulation T3 enters into brain
Effects on Muscles :
? Increase in thyroid hormones weaken the muscle due to excess
protein catabolism.
? Lack of hormones lead to sluggish and delayed relaxation of
muscles after contraction.
Effects on sleep:
Thyroid hormone excess produce increased reactivity of the
neuronal synapses leading to insomnia. In hypothyroidism somnolence is
a characteristic feature.
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Effects on other Endocrine glands [25]:
? Increases insulin secretion from pancreas and has secondary effects
on glucose metabolism
? Increases PTH – which increases many metabolic activities related
to bone formation
? Thyroid hormone increases ACTH levels by increasing the
metabolism of adrenal glucocorticoids in the liver.
Effects on gonadal function :
It has direct metabolic effects on the gonads and indirectly through
anterior pituitary hormones that regulate gonadal function.
Other functions:
? Conversion of beta carotene to vitamin A
? Metabolism of glycosaminoglycans
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Table 4: Physiologic Effects of Thyroid Hormones
Target
Tissue
Effect Mechanism
Heart Chronotropic
Inotropic
Increased number of adrenergic
receptors
Enhanced responses to circulating
catecholamines
Increased proportion of myosin heavy
chain (with higher ATPase activity)
Adipose
tissue
Catabolic Stimulated lipolysis
Muscle Catabolic Increased protein breakdown
Bone Developmental Promote normal growth and skeletal
development
Nervous
system
Developmental Promote normal brain development
Gut Metabolic Increased rate of carbohydrate
absorption
Lipoprotein Metabolic Formation of LDL receptors
Other Calorigenic Stimulated oxygen consumption by
metabolically active tissues
(exceptions: testes, uterus, lymph
nodes, spleen, anterior pituitary)
Increased metabolic rate
Courtesy : Ganong’s Review of Medical physiology 23 rd edition.
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Hypothyroidism :
Hypothyroidism is due to deficiency of thyroid hormone secretion
and action. Women are more affected than men and the incidence
increases with age. Myxoedema is the adult form of hypothyroidism
characterised by accumulation of mucopolysaccharides in the tissues and
skin which leads to swelling and thickening of the skin. Cretinism is the
severe form of hypothyroidism that occurs in infants.
Primary hypothyroidism:
It  is  caused  by  structural  or  functional  abnormalities  of  thyroid
gland. Diseases of the gland or any treatment that destroys thyroid tissue
interferes with hormone synthesis and action.
Secondary hypothyroidism:
Diseases of the pituitary and hypothalamus cause decreased TSH
secretion and leads to hypothyroidism.
Symptoms:
? Tiredness, weakness, Fatigue
? Dry skin
? Feeling cold
? Hair loss
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? Poor memory and difficulty in concentrating
? Constipation
? Weight gain with poor appetite
? Dyspnea
? Hoarseness of voice
? Menorrhagia
? oligomenorrhea or amenorrhea
? Paresthesia
? Impaired hearing
Signs
? Dry coarse skin
? cool peripheral extremities
? Puffy face, hands, and feet (myxoedema)
? Diffuse alopecia
? Bradycardia
? Peripheral edema
? Delayed tendon reflex relaxation
? Carpal tunnel syndrome
? Serous cavity effusions
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Causes :
     There are various causes for hypothyroidism. It is divided into
primary causes and secondary causes. Iodine deficiency is the most
common cause for hypothyroidism. In iodine sufficient areas autoimmune
disease is the most common cause. Approximately 99 % of cases are due
to primary hypothyroidism [12].
Hypothyroidism
       Primary cause        Secondary cause
    Goitrous        Nongoitrous     Pituitary      Hypothalamus
Primary causes of Hypothyroidism:
? Nongoitrous :[ loss of thyroid tissue]
? Surgical removal of thyroid gland
? Radioablation for toxic goiter or cancer
? Autoimmune thyroiditis
? Thyroid gland dysgenesis
? Thyroid gland hypoplasia
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? Goitrous : [decrease in thyroid hormone synthesis ]
? Dietary deficiency of iodine
? Intake of goitrogens
? Drugs like :
? Lithium
? Iodine [wolff chaikoff’s effect][7]
? Antithyroid agents
? Sodium or Pottasium perchlorate
? Paraamino salicylic acid
? Phenylbutazone
? Aminoglutethimide
Secondary causes :
? Pituitary :[deficient TSH production]
? Trauma
? Injury
? Infarct
? Infection
? Tumors
? Hypothalamus :[deficient TRH production]
? Trauma
? Injury
? Infection
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Iodine requirement and deficiency :
? Recommended Dietary Allowances for iodine
? Adults – 150 microgram/day
? Pregnancy – 220 microgram/day
Iodine deficiency is most common in the mountainous areas
because of low iodine content in soil and water. Ingested iodine is
converted to iodide and absorbed from gut . 80 % of ingested iodine is
excreted through kidneys. Only 20 % of iodine is utilized for thyroid
hormone synthesis by the gland .
Lack of iodine
No production of triiodothyronine and thyroxine
No feedback control to inhibit TSH
? TSH secretion by pituitary and stimulates follicular
cells to secrete thyroglobulin
? Follicular size and thyroid gland enlarges 10 to 20 times than normal
Goiter
FIGURE 4 : IODINE METABOLISM
Courtesy : Ganong 23 rd edition.
Endemic goiter is usually due to Iodine deficiency. Enlargement of the thyroid gland
is called goiter .
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Grading of Goiter :
Grade 0 : No visible or palpable swelling
Grade  1  : No visible but palpable swelling when the neck is in normal
position.
Grade  2  : swelling is visible and palpable when the neck is in normal
position
Grade 3 : the struma is very large and extends into retrosternal region
Table salt is iodised one part of Sodium Iodide to every 1,00,000
parts of sodium chloride to prevent iodine deficiency. [30].
Goitrogenic Foods :
Ingredients present in naturally occurring foods which prevents
utilization of Iodine in the diet are called goitrogens. Generally
goitrogenic foods are divided into two categories: soybean-related foods
and cruciferous vegetables. Also strawberries, millet, peaches contain
goitrogens which is not included in this category.
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Goitrogenic foods Goitrogens Mechanism
Millet, soybeans Flavonoids Inhibits
thyroperoxidase
Cruciferous  Vegetables :
Cabbage, Cauliflower, Broccoli,
turnips
Thiocyanates Inhibits Iodine
uptake of thyroid
Cassava meal cyanogenic
glycoside
converted to
thiocyanates
    Inhibits Iodine
uptake of thyroid
Autoimmune thyroiditis :
      Among autoimmune thyroiditis hashimoto’s is the most common. Its
prevalence is 4 per 1000 women and 1 per 1000 men [33].  It  is  more
common in females than males and increases with age. Presence of
autoantibodies to either thyroid peroxidase, thyroglobulin or TSH
receptors. In this condition lymphocytic infiltration occurs in the thyroid
gland. Lymphocytic infiltration is composed of CD4, CD8, T cells and B
cells. T cells produces cytokines which includes tumor necrosis factor,
interleukins, interferon gamma. This stimulates follicular cells to undergo
apoptosis. Thyroid cell destruction is mainly caused by CD8- cytotoxic T
cells either by apoptosis or perforin induced cell necrosis[33]. This causes
atrophy of thyroid follicles and leads to fibrosis. So there is impaired
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secretion of thyroid hormones. This condition is diagnosed by elevated
TPO antibodies and confirmed by thyroid biopsy.
Risk factors : [33]
? Genetic susceptibility – HLA DR polymorphism individuals
? Age
? Female sex – due to sex steroid effects on immune response
? Infection
? Pregnancy - post partum thyroiditis
? Drugs - Iodine , Amiodarone
EVALUATION OF HYPOTHYROIDISM
Courtesy : Harrison’s 18 th edition
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Complications of Hypothyroidism :
Infertility :
Hypothyroidism affects ovulation and impairs fertility.
Birth defects :
Hypothyroidism during pregnancy affects brain and physical
development of the fetus. Hypothyroidism should be diagnosed by
newborn screening as early as in the neonatal period to prevent
developmental complications.
Heart problems :
Hypothyroidism increases LDL cholesterol in the plasma and can
lead to atherosclerosis and myocardial infarction. Hypothyroidism can
also lead to cardiac enlargement, cardiac failure and pericardial effusion.
Mental health :
Hypothyroidism gradually decreases mental functioning and leads
to depression.
Peripheral neuropathy :
Peripheral nerves may get damaged if long term uncontrolled
hypothyroidism occurs. Symptoms are pain, numbness and tingling
sensation over the affected area. It also leads to muscle weakness.
Myxoedema :
It is a rare, emergency and life threatening condition. Symptoms
and signs include extreme fatigue, intense cold intolerance, drowsiness
and unconsciousness.
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Homocysteine :
Homocysteine is the sulphur containing aminoacid which is formed
as an intermediate in the methionine metabolism. Methionine is an
essential aminoacid and is the only source of homocysteine in the human
body. Only small amount of homocysteine is present in free form,
approximately 80 % are protein bound. Animal protein contains twice the
amount of methionine than in plant protein.
Homocysteine Structure :
It is an aliphatic mono amino mono carboxylic aminoacid. It is a
derived aminoacid.
Homocysteine Metabolism :
    Homocysteine metabolism involves one of the two pathways : [26]
   - Transmethylation
   - Transsulfuration
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Transmethylation pathway :
Homocysteine is converted to methionine by the enzyme
methyltetrahydrofolate - homocysteine methyl transferase and betaine –
homocysteine methyl transferase which is present only in liver [27,28]. In
this reaction methyl tetrahydrofolate and vitamin B12 acts as a cofactor.
This is a reversible reaction . Methyl transferase enzyme has Km of < 0.1
mmol/L and has high affinity for homocysteine even in low
concentration[27,28]. Methionine is converted to its active form S-adenosyl
methionine by methionine adenosyl transferase . High concentration of S-
adenosyl methionine inhibits methyl transferase and is the methyl donor
for transmethylation reaction.
Transsulfuration pathway :
Homocysteine is metabolised to cysteine with the help of two
vitamin B6 dependent enzymes. The Km of cystathionine ? synthase is >
1mmol/L and has low affinity for homocysteine. It is converted to
cysteine only in high concentration[27,28].This cysteine is further
metabolised and excreted in the urine. Transsulfuration pathway is
irreversible and this pathway is present only in liver, kidney, pancreas
and small intestine [29].
FIGURE 5 : HOMOCYSTEINE METABOLISM
Courtesy: KILLIAN ROBINSON. Homocysteine, B vitamins,
and risk of cardiovascular disease.
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Hypothyroidism and Homocysteine :
Plasma total homocysteine level is increased in hypothyroidism
and decreased in hyperthyroidism[31,32]. Hypothyroidism decreases the
enzyme involved in remethylation pathway of homocysteine and thus
leads to hyperhomocysteinemia[34]. Thyroid hormones stimulate
flavokinase involved in the synthesis of flavin adenine mononucleotide
and flavin adenine dinucleotide[35,36,37].
In hypoyhroidism there is defective conversion of riboflavin to its
FAD co-enzyme[38]. Methylene tetrahydrofolate reductase is the
flavoprotein enzyme that converts methylene THF to methyl THF. The
methyl THF is necessary for methylation of vitamin B12 and further
conversion of homocysteine to methionine. MTHFR activity is decreased
in hypothyroid individuals which leads to hyperhomocysteinemia[39,40].
N5, N10 Methylene THF
Methylene THF reductase
N5 Methyl THF
Cobalamin     Methyl cobalamin
Homocysteine    Methionine
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Thyroid hormone replacement therapy in hypothyroidism
decreases homocysteine level [41,42]. Normalization of homocysteine
usually occurs after 3-9 months of therapy[43].
Homocysteine on hypothyroidism :
Total plasma homocysteine levels [micromoles/L ] :
? 10 ?mol/L - Normal
? 10-12 ?mol/L - Mild hyperhomocysteinemia
? 12-30 ?mol/L - Moderate hyperhomocysteinemia
? 30-100 ?mol/L - Intermediate hyperhomocysteinemia
? >100 ?mol/L – Severe hyperhomocysteinemia [10]
The reference range of total plasma homocysteine level has
changed from 5-15 ?mol/L to 5-10 ?mol/L in recent times.
Hyperhomocysteinemia is defined as > 10 ?mol/L[44].  Mccully  was  the
first person to report an association between hyperhomocysteinemia and
atherosclerosis[45]. For atherothrombotic and atherosclerotic vascular
diseases mild hyperhomocysteinemia is an independent risk factor [46,47].
There is a dose – response relationship between homocysteine and
atherosclerosis. For each 5 ?mol/L increase in homocysteine there is a 33
% risk of developing atherosclerosis [48,49].
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In protein synthesis by fautly mechanism methionine may be
replaced by homocysteine because of structural similarity. This will be
recognised by one of the site of Methionyl tRNA synthetase and forms
thioester bond during error-editing reaction and produces homocysteine
thiolactone which is removed by Methionyl tRNA synthetase [50].
Homocysteine thiolactone is a highly reactive molecule which
causes LDL cholesterol to aggregate and then phagocytosed by vascular
macrophages present in early atherosclerotic plaques to form foam cells.
Then homocysteine thiolactone is released from foam cells and produce
free radicals [51]. Homocysteine thiolactone induces endothelial cell
apoptosis independent of caspase pathway [52]. Endothelial cells are very
sensitive even to mild increase in homocysteine concentration because of
absence of cystathionine ? synthase activity. Homocysteine thiolactone is
a irreversible inhibitor of lysyl oxidase and impairs extracellular matrix
maturation [53].
FIGURE 6 : HOMOCYSTEINE THEORY OF ARTERIOSCLEROSIS
Courtesy : Andrew U. Chai M.D., Jonathan Abrams M.D. Preventive
Cardiology Homocysteine: A new cardiac risk factor ?
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Homocysteine induced atherogenesis include [54]:
? Endothelial damage
? Platelet activation
? Smooth muscle proliferation
? Endothelial – leukocyte interactions
Endothelial damage:
The endothelium maintains vascular homeostasis by several
mechanisms. Any injury or damage to endothelial cell disrupts the normal
function of endothelium resulting in leukocyte and platelet adhesion,
thrombosis, smooth muscle proliferation, lipid accumulation and finally
atheroma[6,7,8].
Homocysteine undergoes auto-oxidation catalysed by copper
which results in formation of hydrogen peroxide which is a free radical.
  Homocysteine + NO = nitrohomocysteine
  Homocysteine + LDL oxidized = free radicals of O2
  Superoxide radical o- + NO = peroxynitrites
  Homocysteine + Iron + copper = Superoxide ion + H2O2
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Homocysteine destroys glutathione peroxidase which liberates
H2O2 and decreases the intracellular glutathione causes the imbalance
between oxidized glutathione and reduced one [55].This increases
oxidative stress of endothelial cells and causes damage [56].
FIGURE 7 :  FREE RADICAL PRODUCTION IN
HYPOTHYROIDISM
Generation of Reactive oxygen species :
Generation of free radicals in the vessel wall by vascular smooth
muscle and endothelial cells is mainly due to TNF ? which activates
enzymes like NADPH oxidase and xanthine oxidase. [vinoth 36-43].This
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stimulates the pathways like ASK 1, SERCA. ASK 1 activates MAPK
and NFkB which in turn activates MMP and leads to hypertrophy,
apoptosis and atherosclerosis[99,100].
Effects of endothelial dysfunction :
Nitric oxide:
Endothelial cell
NO
Vasodilatation
Inhibits platelet activation and adhesion
Limits smooth muscle proliferation
Regulates endothelial leukocyte interactions
Initially homocysteine increases synthesis of nitric oxide [57] and
reacts to form S-nitrosohomocysteine[58].  It  has some properties of  nitric
oxide which contributes to its protective mechanism against
atherosclerosis. But prolonged exposure to high homocysteine [59] creates
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a self-perpetuating cycle, because the levels of homocysteine exceeds the
endothelial cell capacity to produce S-nitrosohomocysteine and
oxidatively degrades nitric oxide activity[60]. Antioxidants and folic acid
prevents this homocysteine induced toxicity by maintaining cellular
oxidative metabolism and also folic acid stimulates nitric oxide synthesis.
[13,61]
Glutathione peroxidase :
Glutathione peroxidase catalyses hydrogen peroxide and lipid
peroxides to form their respective alcohol[62,63] and prevents oxidative
stress. Also prevents oxidative degradation of nitric oxide[5]. Among thiol
containing aminoacids homocysteine has an unique property to inhibit
glutathione peroxidase [5].
Haemostasis :
Endothelium synthesizes both anticoagulant and pro-coagulant.
Balance between these two mechanisms is important for maintaining
vascular homeostasis. Normally endothelial surface has
glycosaminoglycans – antithrombin III and thrombomodulin-protein C
complex[64,65]. Also by production of nitric oxide and prostacyclin,
endothelium inhibits coagulation pathway[66].
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In hyperhomocysteinemia, homocysteine stimulates protease
endothelial cell activator of factor V and directly activates coagulation in
the absence of thrombin[67].
Moderate and severe hyperhomocysteinemia reduces endothelial
cell expression of glycosaminoglycans[68]. Homocysteine reduces protein
C concentration because it competes with thrombin for thrombomodulin
binding - component of protein C pathway[69].
Mild hyperhomocysteinemia favours binding of lipoprotein[a] to
fibrin thus reduces plasminogen activation and inhibits fibrinolysis[70].
By all these above mechanisms endothelial cell produces
imbalance and leads to activation of coagulation pathway.
Platelet activation :
There is indirect effect of homocysteine on platelets. Homocysteine
decreases vasodilator nitric oxide concentration by inhibiting its synthesis
and degradation[71] and relieves inhibition of platelet aggregation. In very
severe hyperhomocysteinemia there is increased synthesis of
thromboxane from platelets which is a vasoconstrictor and platelet
aggregator[72].
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Smooth muscle cell proliferation :
Smooth muscle cells are less susceptible to damage by
homocysteine than endothelial cells. Smooth muscle cell proliferation is
stimulated directly by homocysteine or homocysteine-induced platelet
derived mitogenic factors. Mild hyperhomocysteinemia increases
collagen expression in vascular smooth muscle cells[73].
Homocysteine increases synthesis of smooth muscle cells by
involving cyclins and cyclin dependent kinases. Cyclin stimulates
quinescent cells to re-enter the cell cycle and cyclin dependent kinases
which is required for DNA replication[74,75] .
Endothelial-leukocyte interaction :
Homocysteine stimulates neutrophil docking protein complex CD
116 / CD 18 [76] and increase expression of monocyte chemoattractant
protein-1[77].
FIGURE 8 : POTENTIAL ADVERSE EFFECTS OF
HOMOCYSTEINE
Courtesy: J. Thambyrajah and J. N. Townend. Homocysteine and
atherothrombosis — mechanisms for Injury
GAG, Glycosaminoglycan-Antithrombin III anticoagulant pathway;
Protein C/TM, Protein C-Thrombomodulin anticoagulant pathway; TF,
Tissue factor; tPa, tissue plasminogen activator.
51
An overview of Lipoprotein Metabolism : [78]
Lipids are transported in the plasma as lipoproteins. Lipoproteins are
composed of nonpolar lipid core which consists of cholesteryl ester and
triacylglycerol and encircled by single surface layer of amphipathic
phospholipids and cholesterol. There are four major classes of lipids
carried by lipoproteins – cholesteryl ester (36%), phospholipids (30%),
triacylglycerols (16%) , cholesterol (14%) and much less fraction of free
fatty acids.
Four major classes of Lipoproteins :
? Chylomicrons – transports exogenous triglycerides to liver and
extrahepatic tissues.
? Very low density lipoprotein – transports endogenous
triglycerides from liver to extrahepatic tissues.
? Low density lipoprotein – transports cholesterol from liver to
extrahepatic tissues.
? High density lipoprotein – transports cholesterol from peripheral
tissues to liver
Metabolism of Chylomicrons:
Chylomicron is responsible for transport of all dietary lipids. They
are formed in the endoplasmic reticulum of intestinal epithelial cells
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which is mainly composed of triacylglycerols. This is exported to the
lymphatic vessels of the intestine and then to the systemic circulation.
Nascent chylomicrons has apo B48 and accepts apo E and C from HDL
in the circulation.
Chylomicrons are catabolised by lipoprotein lipase which is
present in the blood capillaries, anchored to endothelium by heparan
sulphate. It is present in heart, lung, spleen, adipose tissue, aorta, renal
medulla, diaphragm and lactating mammary gland. This enzyme requires
phospholipids and apo cII as cofactors and triacylglycerol is hydrolysed
to free fatty acids and glycerol. Fatty acids are mainly delivered to heart,
skeletal muscle, adipose tissue (80%) and 20% goes to the liver.
Lipoprotein lipase in heart has high affinity for triglycerides than adipose
tissue.
Insulin stimulates lipoprotein lipase synthesis in adipose tissue and
its translocation to capillary endothelium . The resultant chylomicron
remnant  consists  of  apo  E,  cholesteryl  ester,  cholesterol  and  10-30%  of
triglycerides. This is taken up by receptor mediated endocytosis in the
liver and gets hydrolysed.
Very low density lipoprotein Metabolism :
Very low density lipoproteins are synthesized in the liver and
mainly carries endogenous triglycerides to the extrahepatic tissues.
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Formation of VLDL is similar to the formation of Chylomicrons except
that it is released into the Space of Disse and then to the sinusoids.
Nascent VLDL has apo B100 and accepts apo C and E from HDL in the
circulation.
Triglycerides in the VLDL is metabolised by lipoprotein lipase to
yield fatty acids , glycerol and VLDL remnants – also known as
intermediate density lipoproteins. IDL is either taken up by the liver
through LDL receptor   (apo B100, E) and LDL receptor-related protein
or it is converted to LDL. In humans, most of the IDL is converted to
LDL.
Metabolism of Low density lipoproteins :
LDL is mainly composed of cholesterol and apo B100. LDL
receptors are expressed in liver and many extrahepatic tissues. The
receptors recognize apo B100 in the LDL. Approximately 70% of the
LDL is taken up by the liver and nearly 30% by the extrahepatic tissues.
Alternatively LDL is removed by phagocytes via non specific
endocytosis or scavenger receptors – class A (SRA) and class B, type
1(SRB1) which recognizes altered LDL. This is responsible for
cholesterol deposition in the vessel walls [79].
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Metabolism of High density lipoproteins :
HDL is synthesised from liver and intestine. Intestinal HDL does
not  contain  apo  C  and  E.  It  is  transferred  from  HDL  synthesised  from
liver. The major function of HDL are reverse cholesterol transport and
storage of apo C and E required for chylomicron and VLDL metabolism.
Nascent  HDL  consists  of  phospholipids,  apo  A  and  free
cholesterol. LCAT and apo AI- activator of LCAT binds to the HDL disk.
LCAT converts cholesterol and phospholipids into cholesteryl esters and
lysolecithin. This cholesteryl ester moves into the hydrophobic core of
the bilayer and lysolecithin released into the plasma. This reaction
continues until spherical HDL is formed. HDL3 is smaller and more
denser. HDL3 accepts further free cholesterol from peripheral tissues and
forms HDL2 which is larger and less denser. Concentration of HDL2 is
inversely related to atherosclerosis. Hepatic lipase hydrolyses
triglycerides and phospholipids on the HDL2 and converts to HDL3 after
releasing cholesteryl ester.
Lipid profile in Hypothyroidism :
Thyroid hormone enhances adipose tissue metabolism and
increases production of adipokines.
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? Thyroid hormone stimulates hydroxymethylglutaryl CoA [HMG
CoA] reductase the rate limiting step in cholesterol synthesis and
increases intracellular cholesterol concentration [96].
?  It increases lipoprotein lipase activity which metabolises
triglyceride containing lipoproteins VLDL, IDL and Chylomicrons
into fattyacids and glycerol.
? It affects HDL metabolism by stimulating cholesteryl ester transfer
protein  which  exchanges  cholesteryl  ester  from HDL2 to  VLDL ,
IDL and triglycerides in the opposite direction. Also it increases
hepatic lipase activity which metabolizes HDL2 to HDL3 [80,81].
? Thyroid hormone increases LDL receptor gene expression by
stimulating promoter region of LDL receptor gene which contains
thyroid response element and regulates LDL receptor at mRNA
level [82].
? Increases cholesterol convertion to bile acids and its excretion
through bile.
FIGURE 9 : EFFECTS OF THYROID HORMONE IN
LIPOPROTEIN METABOLISM
Courtesy: Shah Kruti N, Gohil Priyanshee V. Hypothyroidism and
Atherosclerosis: From Etiology to Pathophysiology
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In hypothyroidism lipid metabolism is altered and leads to elevated
total cholesterol inspite of decreased activity of HMG CoA reductase. It
is due to decreased LDL receptor activity and LDL clearance from
plasma[97]..
? Thyroid hormone
? LDL receptor gene activation
Downregulates LDL receptor
? Plasma clearance of LDL
? Plasma total cholesterol
Hypothyroidism decreases the activity of lipoprotein lipase which
is present in the capillaries anchored to the endothelium by heparan
sulphate. Due to its decreased activity metabolism of triglyceride
containing VLDL and chylomicrons are decreased and leads to
hypertriglyceridemia.
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Hypothyroidism
? Lipoprotein lipase activity
?catabolism of VLDL &   chylomicrons
? plasma triglycerides
Hypothyroidism individuals often present with normal or elevated
High density lipoprotein due to decreased activity of hepatic lipase which
catabolizes HDL2 to HDL3 and CETP which exchanges cholesteryl ester
and triglycerides. Normally hepatic lipase activity is inhibited in
premenopausal females by oestrogen and activated by androgens in
males.
Hypothyroidism
? hepatic lipase activity
? catabolism of HDL2 to HDL3
? plasma HDL cholesterol [83]
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Effects of altered Lipid profile on Hypothyroidism :
Hypothyroidism increases low density lipoprotein and promotes
LDL oxidation [84] . 3 % of T4 is bound to plasma lipoproteins. Among
that 0.8 % binds to VLDL, 6.7 % to LDL, 92 % to HDL [85,86]. This T4
bound LDL is protected from oxidation. In hypothyroidism decrease in
T4 level may induce LDL oxidation [87].
Low density lipoprotein is formed from Very low density
lipoprotein after catabolism of triglycerides by lipoprotein lipase and
transfer of apo A1 and apoE to High density lipoprotein. LDL is mainly
composed of cholesterol and apolipoprotein B100. LDL receptors in the
liver and extrahepatic tissues recognise apo B100. LDL receptor is
present in the plasma membrane which is coated with clathrin. After
binding of LDL to the receptor it is internalised into the cell and forms
endosomes which gets fused with primary lysosome to form secondary
lysosome. Protons enter in to lysosome thus decreases pH and separates
LDL from its receptor and the receptor is recycled to the plasma
membrane. The contents of the LDL gets metabolised by enzymes
present in the lysosomes.
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The normal function of LDL is to transport cholesterol from liver
to extrahepatic tissues which is necessary for many functions like
membrane lipids, steroid synthesis , vitamin D synthesis etc.
In hypothyroidism hypercholesterolemia leads to production of
reactive oxygen species that oxidises LDL. This damages endothelial
cells and decreases nitric oxide production that leads to loss of
vasodilatation property. Oxidized LDL favours formation of
atheromatous plaque through number of mechanisms like its cytotoxicity,
chemotactic effects and thrombogenic effects. Oxidized LDL loses its
normal function and gets deposited on arterial walls. This stimulates
immune response and leukocytes migrate to that site and cause
inflammation[88]. Oxidized LDL stimulates formation of matrix
metalloproteinase in vascular endothelium, fibroblast and upregulates the
expression of receptors in endothelial cells which is responsible for foam
cell formation [[102]
Hypercholesterolemia
? Reactive oxygen species
Endothelial damage
? NO
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       The oxidised LDL cannot perform its function and get deposited in
the walls of the arteries. This chemoattracts leukocytes which causes
inflammation and are phagocytosed by macrophages and become foam
cells. Early atheromatous plaque is formed in the arterial walls.
Hypercholesterolemia
Accumulates inside intima
Oxidized by reactive oxygen species
Oxidized LDL recognized by scavenger receptors in macrophages
Phagocytosed and form  foam cells
Toxic to endothelium and smooth muscle cells [88]
Treatment with thyroxine decreases cholesterol level by
upregulation of LDL receptors and increases its excretion through bile.
Thyroxine treatment stimulates reverse cholesterol transport due to
increased activity of CETP and increases HDL2 metabolism by hepatic
lipase, so it decreases HDL levels. Also it inhibits LDL oxidation [89].
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In worldwide, atherosclerosis is one of the leading cause of death
and disability. Arteriosclerosis is a syndrome characterized by the deposit
and infiltration of lipid substances in the medium and large arterial walls.
Is the most common form of arteriosclerosis. Causes an inflammatory
reaction and multiplication and smooth muscle cells migration of the wall
producing ranging narrowing of the arterial lumen and forms atheroma
plaques[88].
Coronary artery atherosclerosis leads to angina pectoris and
myocardial infarction. Cerebral artery atherosclerosis leads to stroke and
cerebral ischemia. Peripheral artery atherosclerosis causes deep venous
thrombosis[90]. The relationship between hypothyroidism and
atherosclerosis was first raised by E.Theodor Kocher in 1883[101].
Hyperhomocysteinemia and dyslipidemia in hypothyroidism leads
to increased free radical production, endothelial dysfunction, decreased
nitric oxide bioavailability, LDL oxidation, deposition of cholesterol in
vessel walls, leukocyte migration, platelet activation and adhesion leading
to local inflammation, formation of foam cells and results in
atheromatous plaque formation.
MATERIALS AND
METHODS
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METHODOLOGY
This cross sectional study was conducted after obtaining Ethical
Committee clearance. All the participants and their relatives were
informed about the study. The study group was selected from
Endocrinology Out-patient Deparment, at Madras medical College and
Rajiv Gandhi Government General Hospital.
Study population:
Cases:
     This study population was divided into three groups.
Inclusion criteria:
Group 1:
It included 30 newly diagnosed hypothyroid individuals of age
around 15-45 years including 26 females and 4 males. This study
population was selected as diagnosed by clinician and confirmed by
thyroid profile [TSH-High,T3,T4-low].
Group 2:
It included 30 hypothyroid patients between > 3 months to < 1 year
duration of treatment. Age around 15-45 years including 29 females and 1
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male. This study population was selected from history of decrease /
absent symptoms of hypothyroidism with normal thyroid profile.
Group 3:
It included 30 controls with age, gender and other confounding
factors like smoking, alcoholism were matched with 26 females and 4
males. They had no symptoms of hypothyroidism with normal thyroid
profile.
Exclusion criteria for both cases and controls:
1. Chronic smokers
2. Pregnancy & lactation
3. Diabetes mellitus
4. Renal disease
5. Liver disease
6. Megaloblastic anemia by peripheral smear and
7. Patients on other medication for a long time were excluded.
Sample collection and storage:
After an overnight fast of about 10-12 hours, 2 ml of blood was
collected from study groups from antecubital vein under an aseptic
precaution. The blood was transferred to EDTA – anticoagulant
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containing test tube upto the mark. Gently shaken the test tube upside
down for uniform mixing.
Samples tubes are labeled and kept in ice box during transportation
to the Biochemistry laboratory. EDTA tubes were centrifuged at 3000 g
for 15 minutes . Plasma was separated from each tube, aliquoted into
Eppendorf tubes within one hour from the collection time. stored at -20 ?
C until analysis of Homocysteine and Lipid profile.
Estimation of Plasma Total Homocysteine :
Method:
Competitive Enzyme linked Immunosorbent Assay[84,91]
Kit used:
Axis-shield Homocysteine EIA. The intra-assay precision is 7 %.
The kit was stored in cold storage room at 4 ?C .
Principle :
? Mixed disulfide and protein-bound homocysteine in the sample are
reduced to free Homocysteine with the use of dithiothreitol.
          DTT
? Protein-ss-Hcy /Hcy-ss-Hcy              Hcy
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? Homocysteine in the sample is converted to S-adenosyl-L-
homocysteine by the reagent containing SAH hydrolase and excess
of adenosine.
      SAH hydrolase
? Hcy + Adenosine   SAH + H2O
? An  immobilized  SAH  was  already  bound  to  the  walls  of  the
microtitre [ELISA] plate.
? Pre-treated standards and samples were added to the wells.
? Then Monoclonal anti-s-adenosyl –L-Homocysteine antibody was
added to the each well. This antibody competes for SAH in the
sample and immobilized SAH.
? Then Bound SAH interacts with enzyme conjugate [Horse Radish
Peroxidase] and substrate.Thus develops the colour.
? The intensity of the colour is inversely proportional to the
concentration of SAH in the standard and the sample.
Reagents:
1. SAH coated microtitre plate 12 * 8 wells
2. SAH standards [2,4,8,15,30,50 micromoles/L] each vial 1.5 ml
3. Assay buffer-54 ml
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4. Adenosine, dithiothretiol reagent -3.5 ml
5. Recombinant SAH hydrolase -3.5 ml
6. SAH hydrolase inhibitor -55 ml
7. Monoclonal mouse SAH antibody -25 ml
8. Enzyme conjugate -15 ml
9. Substrate solution -15 ml
10. Stop solution -20 ml
11. Wash buffer -60 ml [20x]
Procedure:
All the reagents and microtitre strips are equilibrated to the room
temperature before use.
Sample pre treatment procedure:
Sample pretreatment solution was prepared not more than one hour
prior to the start of the assay.
In the first step, assay buffer, adenosine/dithiothretiol, SAH
hydrolase were calculated for 100 samples as Reagent A- 45 ml, Reagent
B-2.5ML, Reagent C-2.5 ml were pipette into the clean beaker and mixed
well.
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Each calibrators / samples were diluted in plastic tubes by adding
25 ?L of calibrators / samples with 500 ?L of sample pre-treated solution
, mixed and incubated for 30 minutes at 37? C. Then followed by the
addition of 500 ?L of enzyme inhibitor to each tubes, mixed and
incubated for 15 minutes at 18-25? C. After the incubation time it was
followed  with  addition  of  500  ?L  of  Adenosine  deaminase,  phenol  red
dye containing reagent , mixed and incubated for 5 minutes at 18-25? C.
This results in pink color. At the end of this step there was formation of
SAH by the enzyme dithiothreitol and SAH hydrolase.
Microtitre plate procedure:
25 ?L of calibrator / sample from the pre-treatment solution were
pipette into the plate wells, which was coated with SAH. Then 200 ?L of
SAH antibody was pipette into the each well and allowed for incubation
for 30 minutes at 18-25? C.  During  the  incubation  period  sample  /
calibrator SAH and coated well SAH are competes for SAH - antibody.
Wash buffer solution were prepared during the incubation period
by diluting with distilled water. 60 ml of wash buffer was added to clean
wash buffer container and followed by 420 ml distilled water [1:9 ratio]
to obtain 500 ml of wash buffer.
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Following the incubation period, ELISA plate was washed with
diluted wash buffer by using 400 ?L for three times using an automated
plate washer. At each wash , complete removal of solution was ensured.
After washing , the wells are blotted on dry tissue paper. This was
followed by the addition of 100 ?L of enzyme conjugate to each well and
incubated for 20 minutes at 18-25? C. This conjugate bound to antigen-
antibody complex. The excess conjugate were removed by washing,
using automated ELISA washer. After washing the wells are carefully
blotted on dry tissue paper.
This step was followed by addition of 100 ?L of substrate solution
to each of the well and allowed for incubation for 10 minutes to react at
18-25? C. After the incubation period the reaction was stopped by the
addition 100 ?L of stop solution that contains 0.8M sulphuric acid and
read the absorbance at 450nm immediately.
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STANDARD CURVE FOR HOMOCYSTEINE
Graph shows homocysteine standard curve with concentration in X
axis against the absorbance in Y axis.
Because of competitive immunoassay, the intensity of the colour is
inversely proportional to the concentration of homocysteine. So the
absorbance is obtained in the decreasing order.
Results :
Optical density and concentration of the standards were read from
ELISA reader. After checking the calibration curve , samples optical
density and concentration were noted. The concentration of homocysteine
is expressed in micromoles /L.
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STANDARD CURVE FOR HOMOCYSTEINE
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Limit of detection:
? 1 micromoles /L
Measuring range:
? 2- 50 micromoles /L
Reference range :
? < 10 micromoles /L
Estimation of TSH :
Method :
Non-competitive Sandwich ELISA
Kit used :
ERBA- Thyro kit
Principle :
Sample was added to the each well which was coated with
streptavidin. Anti-TSH-horseradish peroxidase / biotin conjugate was
added. TSH in the samples forms sandwich between two specific TSH
antibodies. By washing unbound conjugate was removed. By the addition
of substate, developed colour intensity is directly proportional to the
concentration of TSH. Measured photometrically at 450 nm.
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Reagents :
? Streptavidin coated plate – 96 wells
? TSH enzyme reagent
? Wash buffer
? Substrate solution A & B
? Stop solution
? Calibrators – 0, 0.5, 2.5, 5.0, 10, 20, 40 ?IU / L
Reagent preparation :
Wash buffer :
20 ml of wash concentrate is diluted to 1 litre with the distilled
water.
Working substate solution :
Substrate solution A is poured into solution B.
Procedure :
? 50 ?l of calibrators and samples are pipette into the corresponding
well.
? Addition of 100 ?l of TSH enzyme reagent to the each well.
? Mix the microplate gently for 20-30 seconds and incubated at room
temperature for one hour.
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? By using an automatic ELISA plate washer, the plate was washed
for 3 times using 350 ?l of wash buffer.
? Gently blotted on dry tissue paper.
? 100 ?l of working substrate solution was added to the each well
and incubated for 15 minutes at room temperature.
? Then  50  ?l  of  stop  solution  was  added  to  the  each  well  and  mix
gently for 15-20 seconds.
? Measured photometrically at 450 nm.
Calculation of results :
      For standards Optical density was noted. After observing the standard
curve, optical density and concentration of the samples were noted. The
concentration of TSH is expressed in micro international unit / L.
Reference range :
0.4 – 4.8 ?IU / L.
Estimation of Total T3 :
Method :
Competitive Enzyme Linked Immunosorbent Assay
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Kit :
ERBA Thyrokit
Principle :
The sample was added to the each well which has been coated with
streptavidin. T3- horseradish peroxidase conjugate and anti-T3 biotin -
conjugate was added. This antibody conjugate binds to the streptavidin .
During incubation, sample T3 competes with Enzyme T3 conjugate for
anti T3 binding. This complex reacts with substrate to produce colour and
measured photometrically at 450 nm.
The intensity of the colour is proportional to bound HRP-T3
conjugate and inversely proportional to concentration of the T3 in the
sample.
Reagents :
? Steptavidin coated microwell plate
? Total T3 biotin conjugate
? Total T3 anti horse radish peroxidase conjugate
? Substrate solution
? Stop solution
? Wash solution
? Standards -0, 0.5, 1.0, 2.0, 4, 8 ng/ml
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Procedure :
? Pipette 50 ?l of calibrators and samples into the assigned well.
? 50 ?l of T3 enzyme conjugate was added to the each well.
? Then 50 ?l of anti-T3- biotin conjugate was pipette into the each
well.
? Gently shake the plate for 10 seconds and incubate at room
temperature for one hour.
? Then washed the plate by using 350 ?l of wash buffer for 3 times
in automatic washer.
? Gently tapped the plate on dry tissue paper.
? 100 ?l of substate solution was added and incubated for 15 minutes
at room temperature.
? Stopped  the  reaction  by  addition  of  100  ?l  of  stop  solution  to  the
each well.
? Measured photometrically at 450 nm.
Results :
Optical density and calibration curve of calibrators were observed.
Then optical density and concentration of samples were noted. The
concentration of total T3 is expressed in nanograms / ml.
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Reference range :
0.74 – 1.79 ng/ml.
Estimation of Total T4 :
Competitive Enzyme Linked Immunosorbent Assay
Kit :
ERBA Thyrokit
Principle :
The sample was added to the each well which was coated with
streptavidin. Then Biotin-T4 conjugate and anti-T4-HRP conjugate were
added to the well. During the incubation period sample T4 competes with
Biotin-T4 conjugate for the binding site of anti-T4 which binds to
streptavidin in the wells. This anti-T4-HRP-Biotin T4 conjugate reacts
with substrate to produce colour and measured at 450 nm.
The intensity of the colour is inversely proportional to the
concentration of T3 in the sample.
Reagents :
? Streptavidin microwell plates
? Total T4 biotin conjugate
? Total T4 anti HRP conjugate
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? Substrate solution
? Stop solution
? Standards -0, 20, 40, 80, 150, 300 ng/ml
Procedure :
? Pipette 50 ?l of standards and samples into the corresponding
wells.
? Then pipette 50 ?l of T4 – biotin conjugate and anti-T4-HRP
conjugate into all the wells.
? Gently shake the plate for 10 seconds and incubated for one hour at
room temperature.
? At  the  end  of  the  incubation  period  the  plate  was  washed  for  3
times using wash buffer.
? After blotting on the tissue paper 100 ?l of substrate solution was
added.
? After incubation at room temperature for 15 minutes 100 ?l of stop
solution was added.
? Measured photometrically at 450 nm by ELISA reader.
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Results :
After observing the calibration curve optical density and the
concentration of the samples were noted. The concentration of the Total
T4 measured in nanograms/ml.
Reference values :
   47 – 120 ng /ml.
Estimation of other Biochemical parameters:
? Total cholesterol
? Triglycerides
? Low density Lipoprotein -Cholesterol
? High density Lipoprotein –Cholesterol
? Urea
? Creatinine
? Random blood sugar
? Total protein
? Albumin
? Alanine transaminase
? Peripheral smear
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All these parameters were estimated in EM 360 Auto analyzer
using Transasia kit except peripheral smear, it was done by Pathology
Laboratory.
Calibration :
EM 360 auto analyzer was calibrated by using XL multical
calibrator and controls such as Erba norm and Erba path.
Estimation of Plasma Total Cholesterol:
Method :
   Cholesterol Esterase-Oxidase-Peroxidase
Principle:
  Cholesterol Ester is hydrolysed by Cholesterol Esterase to form
Cholesterol and then oxidized by cholesterol oxidase to form
cholestenone and hydrogen peroxide. This hydrogen peroxide react with
phenol and aminoantipyrine to produce pink colored complex and
quantitated at 505 nm.
Cholesterol Esterase
Cholesterol Esters        Cholesterol + fatty acids
          Cholesterol Oxidase
Cholesterol + O2     Cholest-4-en-3-one + H2O2
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Peroxidase
2H2O2 + Phenol + 4 AAP Quinoneimine Dye + 4H2O
Reagent composition:
? Cholesterol Esterase ? 200 U/L
? Cholesterol Oxidase ? 50 U/L
? Peroxidase ? 3000 U/L
? Phenol 5 mmol/L
? 4-Aminoantipyrine    0.3 mmol/L
? Goods Buffer 50 mmol/L
Expected values :
? Desirable   - < 200 mg/dl
? Border line  - 200- 239 mg/dl
? High - > 239 mg/dl
Linearity :
Upto 695 mg/dl
Estimation of Plasma Triglycerides :
Method :
Glycerol phosphate oxidase method
80
Priniciple :
Triglycerides are hydrolysed by lipoprotein lipase to form glycerol.
Then acted upon by glycerol kinase to produce glycerol-3-phosphate,
which on action by oxidase produces hydrogen peroxide and DHAP.
Hydrogen peroxide reacts with 4-aminoantipyrine to produce pink
colored complex and measured at 546 nm. The intensity of the color is
directly proportional to the concentration of triglycerides in the sample.
 Lipoprotein Lipase
Triglyceride + H2O   Glycerol + Fatty acids
 Glycerol kinase
Glycerol + ATP   Glycerol-3-phosphate + ADP
   Glycerol-3-phosphate oxidase
Glycerol-3-phosphate + O2 DHAP + H2O2
Peroxidase
H2O2 + 4-AAP + TOOS       Quinoneimine dye + H2O
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Reagent composition :
R1
? Glycerol kinase ?? 1.5 U/ml
? Glycerol-3-phosphate oxidase ? 6 U/ml
? PIPES buffer ? 50 mmol/L
? ATP 2.85 mmol/L
? Mg 60 mmol/L
? TOOS 0.48 mmol/L
R2
? Peroxidase          ? 15 U/L
? Lipoprotein Lipase ? 25 U/L
? 4-Aminoantipyrine 1.5 mmol/L
Expected values :
? Male : 40-160 mg/dl
? Female : 35-135 mg/dl
Linearity :
  Upto 1000 mg/dl
82
Estimation of plasma HDL Cholesterol :
Method :
  Direct method
Principle :
The assay is based on use of polyvinyl sulfonic acid and
polyethylene glycol methyl ether coupled classic precipitation method.
LDL,  VLDL,  Chylomicrons  in  the  sample  react  with  PVS and  PEGME
and makes inaccessible for cholesterol esterase and oxidase . So the
enzyme selectively reacts with HDL to produce cholesterol and hydrogen
peroxide respectively. Hydrogen peroxide react with 4-AAP to give color
complex and measured at 600 nm. The intensity of the color is directly
proportional to the HDL concentration in the sample.
    PVS,PEGME
HDL + VLDL + LDL + CM HDL +
                     [LDL+VLDL + CM] .PVS / PEGME
Cholesterol Esterase
HDL Cholesterol + Fatty acid
        Cholesterol Oxidase
Cholesterol + O2 Cholest-4-en-3-one + H2O2
                                 Peroxidase
 H2O2 + 4-AAP + TODB   Quinoneimine + 5 H2O
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Reagent composition :
R1
? Polyvinyl sulfonic acid  50 mg/L
? Polyethylene-glycol-methyl ester   30 ml/L
? Mgcl2 2 mmol/L
? MES buffer [pH 6.5] 6.5 mmol/L
R2
? Cholesterol Esterase       5000 U/L
? Cholesterol Oxidase       20 kU/L
? Peroxidase   5 kU/L
? 4-Aminoantipyrine        0.9 g/L
? MES buffer [pH 6.5]       6.5 mmol/L
? Detergent   0.5 %
Expected values :
? Male : 35-80 mg/dl
? Female : 42-88 mg/dl
Linearity :
  Upto 190 mg/dl
84
Calculation of LDL cholesterol :
LDL cholesterol was calculated by using Friedwald’s formula.
LDL cholesterol (mg/dl) = Total cholesterol - [Triglycerides / 5 +
HDL cholesterol]
[Triglycerides < 400 mg/dl]
Body mass index Calculation :
We measured Height and Weight of the each individual in the
study groups to calculate BMI.
???? ?????? ?? ??? ??????? (??)
BMI ??/?2 =
          (?????? ?? ??? ???????)2 (?2) .
Urea estimation :
Method :
   Urease – Glutamate Dehydrogenase
Principle :
Urea is hydrolysed by urease enzyme into ammonia and carbon
dioxide. Then ammonia combines with alpha ketoglutarate in the
presence of reduced nicotinamide adenine dinucleotide and glutamate
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dehydrogenase to produce L-glutamate. The rate of decrease in
absorbance at 340 nm as NADH is converted to NAD is measured.
 Urease
Urea + H2O    2NH3 + CO2
       Glutamate
 Dehydrogenase
NH3 + ? Ketoglutarate + NADH L-Glutamate + NAD
Reference values :
   15 – 40 mg/dl
Linearity :
   Upto 300 mg/dl
Creatinine estimation :
Method :
Modified Jaffe’s method
Principle :
Creatinine reacts with alkaline picrate to produce red colour and
measured at 505 nm by using Kinetic method.
Reference values :
? Males : 0.7 – 1.3 mg/dl
? Females : 0.6 – 1.1 mg/dl
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Linearity :
   Upto 18 mg/dl
Estimation of blood sugar :
Method :
Glucose oxidase – Peroxidase
Principle :
Alpha D-glucose is converted to beta D- glucose by the enzyme
mutarotase. In the presence of glucose oxidase beta D- glucose converted
to glucoronic acid and hydrogen peroxide. By the enzyme peroxidase
hydrogen peroxide combines with phenol and 4-aminoantipyrine to
produce red colour complex and measured at primary wavelength – 505
nm and secondary wavelength at 660 nm.
   Mutarotase
? D-Glucose ? D-Glucose
 Glucose Oxidase
? D-Glucose + H2O + O2 Glucoronic acid + H2O2
        Peroxidase
H2O2 + phenol + 4- Aminoantipyrine Red dye + 2H2O
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Reference values :
   < 140 mg/dl
Linearity :
   Upto 500 mg/dl
Estimation of Total serum protein :
Method :
Biuret method
Principle :
Protein reacts with copper salts in the alkaline medium to produce
violet-blue coloured complex. The intensity of the colour is directly
proportional to the protein concentration and it is measured at 540 nm.
Reference range :
6 – 8 mg/dl
Linearity :
Linear up to 10 g/dl
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Estimation of serum Albumin :
Method :
Bromo cresol green method
Principle :
Albumin in a slightly acidic pH in the presence of bromocresol
green produces colour change from yellow to green-blue and measured at
620 nm. The intensity of the colour is directly proportional to the albumin
concentration in the sample.
Reference range :
  3.5 – 5.2 mg/dl
Linearity :
  Upto 8 g/dl
Estimation of Alanine Transaminase :
IFCC, without pyridoxal phosphate
Principle :
The amino group transferred from Alanine to 2-Oxoglutarate to
produce pyruvate and L-Glutamate. In the presence of lactate
dehydrogenase and reduced nicotinamide adenine dinucleotide, pyruvate
converted to lactate and NAD. The rate of decrease in absorbance due to
oxidation of NADH is measured at 340 nm.
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    Alanine transaminase
 L-Alanine + 2-Oxoglutarate pyruvate + L-Glutamate
    Lactate Dehydrogenase
Pyruvate + NADH L-Lactate + NAD+
Reference range :
  < 45 U/L
Linearity :
   Linear upto 1600 U/L.
Peripheral smear[92]:
Blood films are made on clean glass slides which measures 75* 25
mm and 1 mm thick. After placing a small drop of EDTA blood about 1
cm from one end of the slide in the center line, by using spreader at 30 ?
in front of the drop, moved to make contact with drop and spread the drop
of blood along the slide. The blood film is about 3 cm in length. The glass
slides are allowed to dry in the air. Addition of 8 drops of staining
solution which is the mixture of ethanol and Leishman’s stain and wait
for 5-7 minutes. Then add 16 drops of buffered water and kept for 2
minutes. Then the slide was washed in thin running water and set in
upright to dry. After drying the slide was placed in the microscope under
100x oil emersion field to ruled out features of Megaloblastic anemia.
STATISTICAL ANALYSIS
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STATISTICAL ANALYSIS
? Data was analysed using SPSS 16 statistical software and
considered as statistically significant if the p value is < 0.05.
? ANOVA was used to compare Age, Body mass index, Fasting lipid
profile, TSH, Homocysteine levels between three groups.
? Post HOC test was used to compare Age, Body mass index, Fasting
lipid profile, TSH, Homocysteine levels between two groups.
? Correlation of TSH with Homocysteine and other parameters was
done by using Pearson Correlation Coefficient.
RESULTS
MASTER  CHART
Characteristics  and  Biochemical  parameters  of  Newly  Diagnosed  Hypothyroidism
S
 No Age Sex BMI
TSH
??IU/ml)
T3
(ng/ml)
T4
(ng/ml)
Hcy
??Mol/l)
Chol
(mg/dl)
TGL
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
Total
protein
(g/dl)
Alb
(g/dl)
SGPT
(IU/L)
Urea
(mg/dl)
creat
(mg/dl)
sugar
(mg/dl)
HB
(g/dl)
Peripheral
smear
1 24 F 32.2 98.5 0.21 31.6 13 182 182 62 83.6 6.5 3.6 40 18 0.7 82 9.6 N
2 23 F 41.5 35.1 0.6 38.3 17 164 111 63 78.8 6.2 3.5 15 24 0.8 95 10.2 N
3 32 F 32.5 25.9 0.4 36 11.5 170 69 66 90.2 6.1 3.4 18 20 0.6 76 10.5 N
4 18 M 28.7 8.6 0.67 38 12 139 139 50 61.2 7.3 3.6 23 23 0.8 88 10 N
5 41 F 31.2 17.2 0.5 40 8 240 318 78 98.4 7.1 3.8 28 26 1 112 10.6 N
6 35 M 27.7 17.4 0.43 32 13 143 209 55 46.2 6.3 3.6 23 28 0.8 101 13.9 N
7 29 F 26.7 42.9 0.62 42.5 11.5 158 149 62 66.2 6.2 3.9 36 20 0.9 96 10.2 N
8 38 F 29.5 16.2 0.62 40 10.9 152 70 63 75 6 3.4 34 24 0.8 104 10.4 N
9 28 F 27.1 8.5 0.6 42 19.5 145 99 61 64.2 7.4 4.1 14 30 0.7 100 9.8 N
10 27 F 31.2 14.6 0.5 34 15 178 92 74 85.6 6.8 3.7 19 35 0.9 93 9.6 N
11 35 F 33.2 10.2 0.65 31 10 221 156 88 101.8 6.3 4 20 38 1 60 9.5 N
12 45 F 21 51 0.31 31 9.5 212 300 76 76 6 3.5 37 27 0.72 92 9.5 N
13 30 F 33.2 48.8 0.35 37 10.2 125 139 53 44.2 6.3 3.8 28 18 0.6 105 9.1 N
14 30 F 17.3 18.6 0.57 37 7.4 237 145 99 109 6.5 3.7 27 22 0.8 98 10.3 N
15 27 F 32 6.7 0.68 42 9.2 181 201 69 71.8 7.2 3.8 31 31 0.9 78 11.1 N
16 19 F 16.6 10.5 0.3 31 9.7 134 52 66 57.6 7 3.9 38 16 0.7 86 11.3 N
17 36 F 17.4 16.8 0.2 27 8 183 100 89 74 6.9 4 32 21 0.74 90 11.5 N
18 28 F 21.2 150 0.7 30 8.3 156 188 62 56.4 6.2 3.7 19 26 0.61 96 10.6 N
19 40 F 23.7 56.9 0.4 36.3 9.4 139 292 49 31.6 6.8 3.6 18 33 0.76 87 9.7 N
20 32 F 24.8 200 0.2 34 12.4 174 130 68 80 6.1 3.6 26 30 0.81 106 9.9 N
21 24 F 18.1 150 0.16 36 7 167 64 69 85.2 6.4 3.7 27 28 0.85 110 10.4 N
22 27 M 23.9 88 0.2 32 9 143 199 53 50.2 7.4 4.1 29 32 1.2 108 11.2 N
23 29 F 29.3 9.5 0.68 42 10.2 171 169 56 81.2 6.5 3.6 32 19 0.6 96 10.2 N
24 43 F 24.8 17.5 0.6 35 10.2 111 332 37 7.6 6.6 3.7 35 27 0.71 89 10.4 N
25 25 M 22 100 0.55 27 23.6 117 79 47 54.2 6 3.4 24 24 0.6 80 12.8 N
26 29 F 31.1 7.3 0.5 42 9.3 189 199 44 105.2 7.1 3.5 26 25 0.63 84 11.4 N
27 45 F 30 13.4 0.6 43 11.5 207 169 54 119.2 6.8 3.7 34 19 0.7 97 11.5 N
28 30 F 29.9 100 0.34 20 12 226 142 52 145.6 6.2 3.8 33 22 0.65 95 9.2 N
29 18 F 21.1 7.9 0.3 31 14 144 113 62 59.4 6.5 3.8 25 26 0.84 102 9.5 N
30 30 F 24 15 0.2 37 17 220 170 36 150 6.4 3.6 19 24 0.81 100 10.2 N
MASTER  CHART
Characteristics  and  Biochemical  parameters  of treated Hypothyroidism
S
 No Age Sex BMI
TSH
??IU/ml)
T3
(ng/ml)
T4
(ng/ml)
Hcy
??Mol/l)
Chol
(mg/dl)
TGL
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
Total
protein
(g/dl)
Alb
(g/dl)
SGPT
(IU/L)
Urea
(mg/dl)
creat
(mg/dl)
sugar
(mg/dl)
HB
(g/dl)
Peripheral
smear
1 29 F 20 2.3 0.7 102 7 130 66 54 62.8 6.3 3.8 24 20 0.8 95 12.4 N
2. 32 F 37 3.3 1.14 90 8.2 189 165 56 100 6.1 3.7 31 28 0.7 85 11.5 N
3 33 F 35.5 4.6 0.8 87 11 197 140 48 121 6.7 3.6 30 16 0.7 90 11.8 N
4 35 F 26.6 0.7 0.9 80 8.7 204 99 64 120.2 6.6 3.9 26 15 0.56 75 11.9 N
5 19 F 25.3 3 1.18 109 10.2 121 114 52 46.2 6.8 4 28 18 0.67 123 9.7 N
6 37 F 28.9 4.2 1.25 94 11.5 187 259 63 72.2 6.4 4 25 21 0.81 119 10.5 N
7 20 F 25.7 0.45 0.82 106 11.2 183 136 66 89.8 6.2 3.9 18 20 0.9 132 9.8 N
8 33 F 28.1 1.4 0.78 104 9 239 203 61 137.4 6.3 3.8 30 21 0.7 128 8.6 N
9 25 F 35.9 1.9 0.98 89 4.1 214 185 51 126 6.8 4.3 32 28 1.2 90 9.3 N
10 32 F 23.9 2.7 1.43 105 10 178 155 59 88 6.3 4 26 32 0.6 94 10.8 N
11 38 M 21.8 0.8 1.02 82 11.6 291 89 54 219.2 7.2 4.1 28 30 0.8 82 10.3 N
12 23 F 26.1 3.9 0.96 67 8.4 144 184 57 50.2 7.5 4.4 34 21 0.76 89 12.1 N
13 23 F 24 0.9 0.8 108 11.8 172 72 66 91.6 7.2 3.9 32 22 0.69 98 10.8 N
14 30 F 21.7 2.7 0.6 59 7.6 197 330 67 64 6.9 3.7 19 29 0.84 93 10.3 N
15 30 F 24.7 1.3 0.5 77 8 198 222 47 106.6 7 3.8 17 26 0.91 106 9.6 N
16 25 F 29.2 4.1 0.9 92 7 203 167 60 109.6 7.1 3.9 21 34 1 78 9.8 N
17 45 F 27.2 3.2 0.9 62 10.5 222 136 53 141.8 6.7 3.8 25 30 1.1 86 12.3 N
18 33 F 24.4 4 1.03 109 9 142 111 57 62.8 7.1 4 29 20 0.9 95 10.7 N
19 31 F 24.8 2.7 1.13 90 12 128 64 49 66.2 6.5 3.8 28 24 0.75 98 10.1 N
20 24 F 34.2 0.5 0.84 89 10.2 183 164 58 92.2 7.3 4.1 24 26 0.65 103 12.3 N
21 32 F 31 3.9 1.2 96 8 196 138 55 113.4 6.9 3.8 23 29 0.82 109 10.4 N
22 25 F 28.8 0.5 0.93 116 9.8 205 100 62 123 6.7 3.8 20 21 0.93 79 11.2 N
23 30 F 29.2 3.2 1.04 110 12.3 121 111 61 37.8 6.9 4 24 19 0.81 86 10.8 N
24 18 F 20.1 2.3 0.86 56 11.9 142 122 46 71.6 7.1 3.9 18 17 0.91 74 10.2 N
25 37 F 20.3 1.6 0.92 65 13 135 128 58 51.4 6.9 3.9 16 21 0.72 79 9.7 N
26 17 F 22.1 2.6 0.87 108 9.2 176 136 54 94.8 7 4 26 18 0.82 86 9.4 N
27 29 F 22.1 0.5 0.98 109 11 187 125 57 105 6.8 4 28 20 0.8 88 10.2 N
28 31 F 35.6 1.2 0.99 56 10.9 203 167 46 123.6 6.5 3.8 30 19 0.8 100 12.1 N
29 29 F 23.9 0.9 0.82 63 10.8 214 185 47 130 6.7 3.9 32 18 0.9 104 10.9 N
30 33 F 21.2 2.3 1.05 54 11.3 189 100 56 113 7.2 4.1 27 24 1.1 113 9.8 N
MASTER  CHART
Characteristics and  Biochemical  parameters  of  controls
S
No Age Sex BMI
TSH
??IU/ml)
T3
(ng/ml)
T4
(ng/ml)
Hcy
??Mol/l)
Chol
(mg/dl)
TGL
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
Total
protein
(g/dl)
Alb
(g/dl)
SGPT
(IU/L)
Urea
(mg/dl)
creat
(mg/dl)
sugar
(mg/dl)
HB
(g/dl)
Peripheral
smear
1 28 F 20.1 3.2 0.89 69 8.9 148 142 58 61.6 6.8 3.6 20 30 0.91 96 9.8 N
2 35 M 21.3 0.65 0.79 82 9.2 146 133 87 32.4 7 3.9 15 34 1.1 104 9.6 N
3 45 F 19.4 1.4 0.86 76 10.4 130 127 66 38.6 7.4 4.2 21 17 1 112 10.6 N
4 32 M 20 1.9 1.2 57 9.6 160 106 64 74.8 7.8 4.5 22 20 0.92 96 10.3 N
5 30 F 19.6 2.7 0.93 86 7.3 154 99 62 72.2 6.7 4.1 32 18 0.86 98 9.7 N
6 32 M 21.2 0.5 0.82 90 12 140 77 57 67.6 6.2 4 30 24 0.85 107 9.5 N
7 28 F 20.9 3.2 0.94 91 9 134 98 52 62.4 6.5 3.8 27 22 0.92 103 11.3 N
8 28 F 20.1 2.3 0.9 96 11.2 126 87 49 59.6 6.7 3.7 24 22 1.2 92 12.4 N
9 29 F 20.3 1.6 0.83 64 9.4 101 60 54 35 6.9 3.7 36 18 1.02 86 9.6 N
10 28 F 19.9 3.1 1.3 61 10 132 136 64 40.8 7.1 3.8 24 17 0.92 98 9.8 N
11 25 M 22.6 3.2 1.4 55 10.6 175 101 59 95.8 6 3.6 21 20 0.74 78 10.7 N
12 25 F 20.7 4 1.5 77 9.8 111 82 66 28.6 6.3 3.8 31 32 0.69 105 10.5 N
13 25 F 22.1 2.7 0.94 76 9.4 154 90 56 80 6.4 3.7 32 28 0.72 97 12.4 N
14 24 F 21.6 0.5 0.8 65 10.6 100 51 49 40.8 6.1 3.6 30 25 0.81 92 9.7 N
15 24 F 20.9 3.9 0.96 54 10.1 145 88 64 63.4 6.8 4 24 18 0.75 104 9.8 N
16 33 F 19.8 2.3 1.1 83 8.2 125 61 51 61.8 6.5 4.1 20 25 0.82 112 10.2 N
17 27 F 21 3.3 0.94 85 12.8 147 101 60 66.8 6.4 3.9 21 24 0.73 120 9.6 N
18 27 F 18.7 3.6 0.89 68 10.1 182 71 54 113.8 6.5 3.7 22 19 0.9 94 9 N
19 45 F 21.8 0.7 0.79 95 11.1 176 82 62 97.6 7 4 28 15 0.91 85 10.7 N
20 21 F 20.8 3 0.87 57 7.2 174 132 58 89.6 7.2 4.2 37 17 0.82 94 10.1 N
21 18 F 21.2 3.2 0.99 58 12 123 46 52 61.8 6.8 3.9 34 21 0.76 83 12.3 N
22 35 F 25.3 0.92 0.86 82 6.4 151 54 56 84.2 6.9 4.2 38 20 0.72 100 12.8 N
23 33 F 23.2 1.5 0.84 69 9.1 169 140 58 83 6.5 3.9 18 19 0.87 79 10.2 N
24 26 F 20.9 1.9 0.85 73 9 134 98 52 62.4 6.8 3.7 24 21 0.9 74 13.1 N
25 24 F 20.1 2.7 0.87 78 11.2 126 87 49 59.6 7.1 4.2 31 19 1.1 97 10.9 N
26 27 F 20.3 0.5 0.78 102 9.4 101 60 54 35 7.5 4.3 24 32 1 104 9.9 N
27 28 F 20.8 3.2 1.2 54 7.2 174 132 58 89.6 7.2 4 27 31 0.9 95 9.4 N
28 27 F 21.2 2.3 0.92 65 12 123 46 52 61.8 6.8 3.9 31 30 0.8 114 9.8 N
29 22 F 25.3 1.6 0.87 58 6.4 151 54 56 84.2 6.5 3.8 30 17 0.8 79 10.7 N
30 26 F 23.2 2.2 1.2 80 9.1 169 140 58 83 6.6 4 26 16 0.74 86 10.2 N
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RESULTS
TABLE 5 : CHARACTERISTICS OF CONTROLS,
TREATED HYPOTHYROIDISM  AND RECENTLY
DIAGNOSED HYPOTHYROIDISM
PARAMETERS CONTROLS
TREATED
HYPOTHYROIDISM
RECENTLY
DIAGNOSED
HYPOTHYROIDISM
P VALUE
AGE 28.57 ± 5.85 29.27 ± 6.3 30.57 ± 7.26 0.496
NS
SEX
MALE 4 [13.3 %] 1 [3.3 %] 4 [13.3 %]
FEMALE 26 [86.7 %] 29 [96.7 %] 26 [86.7 %]
BODY MASS
INDEX
21.14 ± 1.53 26.64 ± 5.04 26.8 ± 5.9 <0.001**
TSH [?IU/L] 2.26 ± 1.07 2.26 ± 1.3 45.4 ± 51.02 <0.001**
TOTAL
CHOLESTEROL
[mg/dl]
142.7 ± 23.62 159.6 ± 19.83 170.9 ± 35.5 <0.001**
TRIGLYCERIDES
[mg/dl]
92.7 ± 31.27 145.77 ± 57.32 159.2 ± 74.98 <0.001**
LDL-c [mg/dl] 66.26 ± 21.57 74.31 ± 17.94 76.99 ± 30.5 <0.001**
HDL –c [mg/dl] 57.9 ± 7.45 56.13 ± 6.14 62.1 ± 14.52 0.068
HOMOCYSTEINE
??mol /L]
9.62 ± 1.65 9.84 ± 1.97 11.64 ± 3.72 0.006*
NS – Non significant; * - significant; ** - Highly significant
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Table - 5 shows baseline characteristics and biochemical
parameters of the controls, treated hypothyroidism and recently
diagnosed hypothyroidism cases.
No significant difference were found in the distribution of age and
sex among the study groups. This shows that the study is age and sex
matched.
Highly significant difference was observed between the study
groups in Body mass index, total cholesterol, triglycerides, LDL-
cholesterol, TSH with the p value < 0.001.
There is no significant difference in HDL-cholesterol between the
study groups.
There was significant difference in total plasma homocysteine level
between study groups with the p value 0.006.
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FIGURE 10 : MEAN TSH VALUES IN THREE STUDY GROUPS
Figure 10: shows mean TSH values among three groups. TSH
values are same for controls and treated hypothyroidism. Treated
hypothyroidism subjects are included in this study after they become
euthyroid. TSH value is more in recently diagnosed hypothyroidism cases
compared to controls and treated hypothyroidism.
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FIGURE 11 : MEAN TOTAL CHOLESTEROL LEVELS
IN  THREE STUDY GROUPS
Figure 11: shows mean total cholesterol levels among three study
groups. Recently diagnosed hypothyroidism cases showed high
cholesterol levels compared to controls and treated hypothyroidism.
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FIGURE 12 : MEAN LDL LEVELS IN THREE STUDY GROUPS
Figure 12: shows mean Low Density Lipoprotein – cholesterol
among study groups. LDL-cholesterol is more in recently diagnosed
hypothyroidism cases compared to treated hypothyroidism and controls.
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FIGURE 13 : SHOWS MEAN BODY MASS INDEX
BETWEEN STUDY GROUPS
WHO classification:
Normal BMI = 18.5 to 25 Kg/m2
Over weight = 25 to 30 Kg/m2
Obese class I  (moderately obese) = 30 to 35 Kg/m2
Obese class II (severely obese) = 35 - 40 Kg/m2
Obese class III (very severely obese) = > 40 Kg/m2
Recently diagnosed and treated hypothyroidism were in stage
2 - Over weight. In this study Control group was in normal BMI.
21.14
26.64 26.8
controls Treated
hypothyroidism
Recently  diagnosed
hypothyroidism
BMI
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TABLE 6 :COMPARISON OF CHARACTERISTICS BETWEEN
CONTROLS AND RECENTLY DIAGNOSED HYPOTHYROIDISM
Parameters Controls
Recently
diagnosed
hypothyroidism
p value
AGE 28.57 ± 5.85 30.57 ± 7.26 0.244 NS
SEX MALE 4 [13.3 %] 4 [13.3 %]
FEMALE 26 [86.7 %] 26 [86.7 %]
BODY MASS INDEX 21.14 ± 1.53 26.8 ± 5.9 < 0.001 **
TSH [?IU/L] 2.26 ± 1.07 45.4 ± 51.02 < 0.001 **
TOTAL CHOLESTEROL
[mg/dl]
142.7 ± 23.62 170.9 ± 35.5 0.001 **
TRIGLYCERIDES [mg/dl] 92.7 ± 31.27 159.2 ± 74.98 < 0.001 **
LDL-c [mg/dl] 66.26 ± 21.57 76.99 ± 30.5 0.032 *
HDL –c [mg/dl] 57.9 ± 7.45 62.1 ± 14.52 0.11
HOMOCYSTEINE
??mol /L]
9.62 ± 1.65 11.64 ± 3.72 0.004 *
NS – Non significant *- Significant ** - Highly significant
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Table 6 shows the comparison of characteristics between controls
and recently diagnosed hypothyroidism.
The two groups showed significantly different in body mass index,
total cholesterol, triglycerides, TSH with the p value 0.001.
The two groups were significantly different in LDL-cholesterol
with p value < 0.05.
No significant difference was observed between these two groups
in age, sex, HDL-cholesterol.
Total plasma homocysteine levels were significantly more in
recently diagnosed hypothyroidism [11.64 ± 3.72] than controls [9.62 ±
1.65] with  p value of 0.004.
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FIGURE 14 : GENDER DISTRIBUTION IN RECENTLY
DIAGNOSED HYPOTYROIDISM AND CONTROLS
Figure 14 : shows gender distribution between controls and recently
diagnosed hypothyroidism.
The incidence of hypothyroidism is higher in females compared to males.
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100
TABLE 7 : COMPARISON OF CHARACTERISTICS
BETWEEN RECENTLY DIAGNOSED HYPOTHYROIDISM
AND TREATED HYPOTHYROIDISM
PARAMETERS
RECENTLY
DIAGNOSED
HYPOTHYROIDISM
TREATED
HYPOTHYROIDISM
P VALUE
AGE 30.57 ± 7.26 29.27 ± 6.3 0.448 NS
SEX MALE 4 [13.3 %] 1 [3.3 %]
FEMALE 26 [86.7 %] 29 [96.7 %]
BODY MASS INDEX 26.8 ± 5.9 26.64 ± 5.04 0.919 NS
TSH [?IU/L] 45.4 ± 51.02 2.26 ± 1.3 < 0.001 **
TOTAL
CHOLESTEROL[mg/dl]
170.9 ± 35.5 159.6 ± 19.83 0.005 *
TRIGLYCERIDES
[mg/dl]
159.2 ± 74.98 145.77 ± 57.32 0.366 NS
LDL-c [mg/dl] 76.99 ± 30.5 74.31 ± 17.94 0.085 NS
HDL –c [mg/dl] 62.1 ± 14.52 56.13 ± 6.14 0.024 *
HOMOCYSTEINE
??mol /L]
11.64 ± 3.72 9.84 ± 1.97 0.009 *
NS – Non significant *- Significant ** - Highly significant
101
Table 7 shows comparison of characteristics between recently
diagnosed hypothyroidism and treated hypothyroidism.
Among these two study groups Total cholesterol , HDL-cholesterol
and TSH levels were significant.
Triglycerides, LDL-cholesterol and Body mass index were found
to be not statistically significant between these two study groups.
Total plasma Homocysteine levels were significantly increased in
recently diagnosed hypothyroidism compared to treated hypothyroidism
with p value of 0.009.
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TABLE 8 : COMPARISON OF CHARACTERISTICS BETWEEN
CONTROLS AND TREATED HYPOTHYROIDISM
PARAMETERS CONTROLS
TREATED
HYPOTHYROIDISM
P VALUE
AGE 28.57 ± 5.85 29.27 ± 6.3 0.487 NS
SEX MALE 4 [13.3 %] 1 [3.3 %]
FEMALE 26 [86.7 %] 29 [96.7 %]
BODY MASS INDEX 21.14 ± 1.53 26.64 ± 5.04 < 0.001 **
TSH [?IU/L] 2.26 ± 1.07 2.26 ± 1.3 1.00 NS
TOTAL
CHOLESTEROL[mg/dl]
142.7 ± 23.62 159.6 ± 19.83 0.634 NS
TRIGLYCERIDES [mg/dl] 92.7 ± 31.27 145.77 ± 57.32 0.001 **
LDL-c [mg/dl] 66.26 ± 21.57 74.31 ± 17.94 0.664 NS
HDL –c [mg/dl] 57.9 ± 7.45 56.13 ± 6.14 0.499 NS
HOMOCYSTEINE
??mol /L]
9.62 ± 1.65 9.84 ± 1.97 0.749 NS
NS – Non significant *- Significant ** - Highly significant
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Table 8 shows the comparison of characteristics between
apparently healthy individuals and treated hypothyroidism.
The subjects in these two groups showed highly significant
difference in body mass index and triglycerides with p value of 0.001.
But these two groups were not significantly different in total
cholesterol, LDL-cholesterol, HDL-cholesterol and homocysteine levels
showing that treatment on thyroxine decreases total plasma homocysteine
and lipid profile levels.
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TABLE 9 : TOTAL PLASMA HOMOCYSTEINE LEVELS
BETWEEN
STUDY GROUPS
ANALYTE CONTROLS
TREATED
HYPOTHYROIDISM
RECENTLY
DIAGNOSED
HYPOTHYROIDISM
P
VALUE
Total plasma
homocysteine
??mol/L]
9.62 ± 1.65 9.84 ± 1.97 11.64 ± 3.72 0.006
Table 9 shows the comparison of mean total plasma homocysteine
levels among controls, recently diagnosed and treated hypothyroidism
patients.
Total plasma homocysteine levels showed significantly more in
recently diagnosed hypothyroidism[11.64 ± 3.72] compared to treated
hypothyroidism [9.84 ± 1.97] and with compared to controls [9.62 ±
1.65] with p value of 0.006.
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FIGURE 15: MEAN HOMOCYSTEINE LEVELS
IN THREE STUDY GROUPS
Figure 15: shows mean total plasma homocysteine levels among
study groups. Homocysteine mean value of controls and treated
hypothyroidism are almost same and within the normal range. Treatment
with thyroxine has impact on the homocysteine levels.
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FIGURE 16 : COMPARISON OF TSH AND HOMOCYSTEINE
AMONG THE STUDY GROUPS
Figure 16 : shows comparison between TSH and total plasma
homocysteine levels in study groups. TSH and homocysteine levels are
almost similar in controls and treated hypothyroidism. In recently
diagnosed hypothyroidism cases TSH and homocysteine shows a parallel
rise.
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FIGURE 17 : COMPARISON OF MEAN VALUES OF TSH AND
CHOLESTEROL IN THREE STUDY GROUPS
Figure 17 : shows comparison of TSH and total cholesterol levels
among three study groups. Both are high in recently diagnosed
hypothyroidism compared to controls and treated hypothyroidism.
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FIGURE 18 : COMPARISON OF MEAN VALUES OF
HOMOCYSTEINE AND CHOLESTEROL
AMONG THE STUDY GROUPS
Figure 18 : shows comparison between total plasma homocysteine
and total cholesterol levels in study groups. Both are high in recently
diagnosed hypothyroidism compared to controls and treated
hypothyroidism.
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TABLE 10 : CORRELATION OF TSH WITH HOMOCYSTEINE
AND OTHER PARAMETERS IN STUDY GROUPS
TSH
Body mass index  Pearson Correlation
          Sig.[2-tailed]
          N
.028
.79
90
Homocysteine    Pearson Correlation
Sig.[2-tailed]
N
.174
.10
90
Total Cholesterol  Pearson Correlation
Sig.[2-tailed]
N
.018
.87
90
Triglycerides     Pearson Correlation
Sig.[2-tailed]
N
.13
.22
90
HDL Pearson Correlation
Sig.[2-tailed]
N
.106
.32
90
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Table 10:  shows  Pearson  Correlation  Coefficient.  It  was  done  on
variables like Body mass index, Homocysteine, Total cholesterol,
Triglycerides and HDL cholesterol with TSH in order to measure the
strength of linear relationship between variables.
It is observed that as TSH increases, the concentration of
homocysteine also increases. This is indicated by weak positive
correlation with r = 0.174.
It is also observed that increase in TSH concentration has positive
correlation with Body mass index, Total cholesterol, Triglycerides and
HDL cholesterol. It indicates that as concentration of TSH increases, all
the above variables also increases in the study population.
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FIGURE 19 : COMPARISON OF VARIOUS PARAMETERS
AMONG THE STUDY GROUPS
Figure 19: shows comparison of various parameters like TSH,
Homocysteine, Total cholesterol, Triglycerides, HDL and LDL
cholesterol among the three study groups.
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DISCUSSION
This study was conducted to measure homocysteine level in newly
diagnosed hypothyroid individuals and to correlate them with treated and
control groups. Also in this study homocysteine was correlated with lipid
profile and evaluated whether it can be used as a risk marker for
atherosclerosis.
This study includes three groups.
? Group 1- 30 individuals with recently diagnosed hypothyroidism
? Group 2 – 30 patients with treated hypothyroidism
? Group 3 – 30 Apparently healthy individuals
In group 1, we selected newly diagnosed hypothyroidism based on
thyroid profile with high TSH and low T3,T4 after excluding smoking,
diabetes, liver disease, renal disease and megaloblastic anemia.
In group 2, we selected hypothyroid patients who were treated for a
period of 3 months to 1 year duration were included. This is to know
whether treatment with thyroxine decreases homocysteine level. This
group was selected based on normal thyroid profile after excluding the
above factors.
In group 3 , age and sex matched thirty apparently healthy
individuals were included .
113
ANOVA analysis showed that there was statistically significant
difference in total plasma homocysteine level between the three study
groups. Total plasma homocysteine level was high in newly diagnosed
hypothyroidism compared to treated hypothyroidism and controls with p
value of 0.006.
Post-Hoc test was used to show the difference of total plasma
homocysteine level between the two study groups. Homocysteine was
high in recently diagnosed hypothyroidism [11.64 ± 3.72] compared to
controls [9.62 ± 1.65] with p value of 0.004. . Homocysteine was high in
recently diagnosed hypothyroidism [11.64 ± 3.72] when compared to
treated hypothyroidism  [9.84 ± 1.97] with p value of 0.009.
From the above we confirmed that hypothyroidism is associated
with hyperhomocysteinemia. The causes for hyperhomocysteinemia are :
? In hypothyroidism the activity of flavokinase is decreased which
has an effect on the activity of flavoprotein enzyme methylene
tetrahydrofolate reductase.
? This decreases the conversion of methylene tetrahydrofolate to
methyl tetrahydrofolate which is one of the cofactor for the
conversion of homocysteine to methionine, thus leading to increase
in homocysteine level in hypothyroidism.
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?  While on treatment with thyroxine this enzyme activity is regained
and homocysteine is converted back to methionine.
The  similar  results  were  obtained  by  Bjorn  G.Nedrebo  et  al [47],
Homocysteine level was high in recently diagnosed hypothyroidism and
decreased in treated hypothyroidism. So early diagnosis and treatment of
hypothyroidism may reduce homocysteine levels, which is one of the
cardiovascular risk factor.
? Prolonged exposure to high homocysteine is toxic because the
levels of homocysteine exceeds the endothelial cell capacity to
produce  S-nitrosohomocysteine which has some effects of nitric
oxide in smooth muscle relaxation.
? In hyperhomocysteinemia , homocysteine stimulates protease
endothelial cell activator of factor V and directly activates
coagulation in the absence of thrombin.
? Mild hyperhomocysteinemia favours binding of lipoprotein[a] to
fibrin thus reduces plasminogen activation and inhibits fibrinolysis.
? Homocysteine thiolactone causes LDL cholesterol to aggregate and
then phagocytosed by vascular macrophages to form foam cells.
Homocysteine thiolactone released from foam cells which
produces free radicals and causes endothelial cell damage.
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3-9 months of treatment on thyroxine with appropriate dose
decreases homocysteine level [43].
Homocysteine has weak positive correlation with TSH [r = 0.174].
This indicates that both TSH and homocysteine were in parallel rise in the
study groups.
By ANOVA we observed that total cholesterol was highly
significant between three groups with p value of < 0.001. Total
cholesterol was high in recently diagnosed hypothyroidism. Comparing
two groups by Post-Hoc test showed that recently diagnosed
hypothyroidism [170.9 ± 35.5] has high total cholesterol compared to
controls [142.7 ± 23.62] with p value of 0.001. Also recently diagnosed
hypothyroidism has high cholesterol when compared to treated
hypothyroidism [159.6 ± 19.83] with p value of 0.005.
? In hypothyroidism increased total cholesterol is secondary to
downregulation of LDL receptors [93] that leads to increase in LDL
cholesterol. LDL contains more cholesterol than other lipoproteins,
so the total cholesterol is also increased in hypothyroidism.
? Thyroid hormone upregulates LDL receptors [82] and thus
decreasing LDL cholesterol and also the total cholesterol.
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? Thyroid hormone increases cholesterol conversion to bile acids and
its excretion through bile.
The same results were observed by Ravi shekhar et al [93], with
statistically significant difference of total cholesterol between the study
groups. Total cholesterol was high in newly diagnosed hypothyroidism
and decreased in treated hypothyroidism.
Also  it  has  weak  positive  correlation  with  TSH  [r  =  0.018].  It
indicates that total cholesterol increases with an increase in TSH in the
study groups.
Triglyceride levels are highly significant as acquired by ANOVA
between the three groups with p value of < 0.001.TGL level is high in
recently diagnosed hypothyroidism cases compared to controls and
treated hypothyroidism.
By analyzing the difference between two groups by Post-Hoc test it
is high in recently diagnosed hypothyroidism [159.2 ± 74.98] compared
to controls [92.7 ± 31.27] with p value of < 0.001. It is high in recently
diagnosed hypothyroidism [159.2 ± 74.98] when compared to treated
hypothyroidism [145.77 ± 57.32] with p value of 0.366. Triglycerides
levels was decreased in treated hypothyroid patients but did not reach the
control level.
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? Thyroid hormone stimulates lipoprotein lipase activity which
metabolizes triglyceride containing lipoproteins like Chylomicrons,
VLDL and IDL.
? Thus hypothyroidism decreases the activity of lipoprotein lipase
and leads to hypertriglyceridemia.
The Similar results were obtained by Diekman et al [94] .
It has weak positive correlation with TSH [r = 0.13], indicating that
there is a parallel increase in the study groups.
LDL cholesterol variation is highly significant obtained by
ANOVA with p value of < 0.001. It is high in recently diagnosed
hypothyroidism [76.99 ± 30.5] compared to controls [ 66.26 ± 21.57]
with p value of < 0.001 and also high compared to treated
hypothyroidism [74.31 ± 17.94] with p value of 0.366 by Post-Hoc test.
? Hypothyroidism causes downregulation of LDL receptors, leads to
increase in LDL cholesterol.
? Thyroid hormone increases LDL receptor gene expression by
stimulating promoter region of LDL receptor gene which contains
thyroid response element and upregulates the LDL receptors and
increases its clearance[82].
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The similar results were observed by M.C.Das et al [93], LDL
cholesterol was decreased in treated hypothyroidism but not attained to
the level of the control group.
In this study, by analyzing with ANOVA, HDL cholesterol is not
statistically significant between three study groups with p value of 0.068.
Comparison of recently diagnosed hypothyroidism [62.1 ± 14.52] with
controls [57.9 ± 7.45] by Post-Hoc test with the p value of 0.11 and this is
not statistically significant. By comparison of recently diagnosed
hypothyroidism [62.1 ± 14.52] with treated hypothyroidism [56.13 ±
6.14] by Post-Hoc test with the p value of 0.024 and this difference is
statistically significant.
? Thyroid hormone stimulates hepatic lipase and cholesteryl ester
transfer protein[80,81].
?  Hepatic lipase converts HDL2 to HDL3, which has low cholesteryl
ester and accepts free cholesterol.
?  CETP exchanges cholesteryl ester of HDL and triglycerides of
VLDL/IDL. Because of this exchanging, HDL has low cholesteryl
ester and accepts more cholesterol from peripheral tissues and
converts to cholesteryl ester.
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? In hypothyroidism hepatic lipase and CETP activity is decreased.
Thus leads to increase in HDL concentration probably HDL2 [98]
which has more cholesteryl ester and it is not exchanged with
VLDL, so it cannot accept further free cholesterol from peripheral
tissues. So it also leads to increase in total cholesterol.
? Treatment with thyroxine HDL levels was decreased and attained
the control group levels.
Similar results were observed by Srinivas et al [93]. HDL cholesterol
is high in recently diagnosed hypothyroidism compared to controls and
treated hypothyroidism.
In  this  study,  by  analyzing  with  ANOVA  Body  mass  index  was
highly significant between the three groups with the p value of < 0.001.
By analyzing with Post-Hoc test BMI was significantly different in
recently diagnosed hypothyroidism [26.8 ± 5.9] compared to controls
[21.14 ± 1.53] with p value of <0.001 and not statistically significant
difference when compared to treated hypothyroidism [26.64 ± 5.04] with
p value of 0.919. Indicating that newly diagnosed and treated
hypothyroidism were over weight and the weight was not reduced after
treatment within one year of duration.
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Analyzing TSH by using ANOVA was highly significant between
the study groups with p value of < 0.001.
By  analyzing  TSH  with  Post-Hoc  test  there  was  significant
difference in recently diagnosed hypothyroidism [45.4 ± 51.02] compared
to controls [2.26 ± 1.07] with p value of <0.001. But it was not
statistically significant when the values of recently diagnosed
hypothyroidism was compared with treated hypothyroidism [2.26 ± 1.3]
with p value of 1.00. Indicating that controls and treated hypothyroidism
were in euthyroid state.
CONCLUSION
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CONCLUSION
This study was conducted to measure Homocysteine level in newly
diagnosed hypothyroid individuals and to correlate with treated and
control groups. Also in this study Homocysteine were correlated with
lipid profile and evaluated whether it can be used as a risk marker for
atherosclerosis.
This study includes three groups.
? Group 1- 30 individuals with Recently diagnosed hypothyroidism
? Group 2 – 30 patients with treated hypothyroidism
? Group 3 – 30 Apparently healthy individuals
In group 1, we selected newly diagnosed hypothyroidism based on
thyroid profile with high TSH and low T3,T4 after excluding smoking,
diabetes, liver disease, renal disease and megaloblastic anemia.
In group 2, we selected hypothyroid patients who were treated for a
period of 3 months to 1 year duration were included. This is to know
whether treatment with thyroxine decreases homocysteine level. This
group was selected based on normal thyroid profile after excluding the
above factors.
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In group 3, age and sex matched thirty apparently healthy
individuals were included .
In this study we found that,
? Total plasma Homocysteine level was significantly increased in
recently diagnosed hypothyroidism.
? Total plasma Homocysteine level was near normal in treated
hypothyroidism.
? Total plasma Homocysteine level was normal in control groups.
? Lipid profile was significantly altered in recently diagnosed
hypothyroidism. The parameters like total cholesterol, TGL, LDL
cholesterol and HDL were in higher range as compared to controls
and treated hypothyroidism.
? In this study we found that hypothyroidism is associated with
hyperhomocysteinemia which causes premature atherosclerosis.
? Hypothyroidism is one of the treatable cause for
hyperhomocysteinemia.
? Abnormal lipid profile and hyperhomocysteinemia has synergestic
effect over atherosclerosis [95] .
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? Early diagnosis and treatment of hypothyroidism plays a major role
in preventing the metabolic abnormality and several complications
like infertility, birth defects, cardiovascular disease etc.
? During treatment with thyroxine hypothyroid patients should be
monitored for 1) lipid profile  2)Total plasma homocysteine levels.
? Measurement of total plasma homocysteine level for screening
cardiovascular risk factors and to avoid untoward complications in
hypothyroidism cases is necessary.
? Patients with unexplained hyperhomocysteinemia should be
screened for thyroid status[14].
LIMITATION
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LIMITATIONS OF THIS STUDY
? Because of the financial limits, Vitamin B12 and Folic acid were
not measured in the study groups to rule out its deficiency and
Megaloblastic anemia.
SCOPE FOR
FURTHER STUDY
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SCOPE FOR FURTHER STUDY
? Methylene tetrahydrofolate reductase enzyme activity can be
measured and correlated with plasma Homocysteine level.
? Gene polymorphism of Methylene tetrahydrofolate reductase
enzyme can be studied.
? Oxidized LDL can be estimated and correlated with plasma
homocysteine level.
? Homocysteine level and thyroid function test in coronary artery
disease
? Homocysteine level and thyroid function test in cerebro vascular
disease.
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PROFORMA
Name                     : Sample no. :
Age          :     Date of collection  :
Sex          : Ht :                     Wt :
Add & Phone.no. : LCB:
Duration of symptoms : LMP:
Wt  gain                YES/NO Menstrual irregularity YES/NO
Fatigue/tiredness YES/NO    Constipation YES/NO
Infertility YES/NO  H/o other symptoms-
Renal disease YES/NO Liver disease YES/NO
CVD YES/NO  DM YES/NO
Smoking YES/NO HT YES/NO
 Epilepsy YES/NO Pregnancy YES/NO
H/O drug intake- Metformin, Thiazides, Phenytoin, Carbamazepine,
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If  Thyroxine: duration-                                                    dose-
Other system examination:
       CVS :                                                                    RS:
       Abdomen:                                                          CNS:
       Skin:
INV Details:
1. TSH
2. T3
3. T4
4. LFT-T.Protein
5. Albumin
6. SGPT
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8. TGL
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11. RFT-Urea
12. Creatinine
13. Sugar
14. Hb%
15. Peripheral smear
16. Homocysteine
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tests.
? We are selecting certain cases and if your blood sample is found
eligible, we may be using your blood sample to perform extra tests and
special studies which in any way do not affect your final report or
management.
? The privacy of the patients in the research will be maintained
throughout the study. In the event of any publication or presentation
resulting from the research, no personally identifiable information will
be shared.
? Taking part in this study is voluntary. You are free to decide whether
to participate in this study or to withdraw at any time; your decision
will not result in any loss of benefits to which you are otherwise
entitled.
? The results of the special study may be intimated to you at the end of
the study period or during the study if anything is found abnormal
which may aid in the management or treatment.
Signature of investigator Signature of participant
PATIENT CONSENT FORM
Title of the study:
A STUDY ON ALTERED TOTAL PLASMA
HOMOCYSTEINE LEVEL AND  LIPID PROFILE  IN  NEWLY
DIAGNOSED HYPOTHYROID INDIVIDUALS
Name        : Date :
Age        : OP No :
Sex        : Project Patient No :
Institution :
? The details of the study have been provided to me in writing and
explained to me in my own language.
? I confirm that I have understood the above study and had the
opportunity to ask questions.
? I understand that my participation in the study is voluntary and
that I am free to withdraw at any time, without giving any reason,
without the medical care that will normally be provided by the
hospital being affected.
? I agree not to restrict the use of any data or results that arise from
this study provided such a use is only for scientific purpose(s).
? I have been given an information sheet giving details of the study.
? I fully consent to participate in the above study.
Signature of investigator Signature of participant
??????? ????? ????
??????? ?????: ??? ?? ????? ?????? ??????
????? ?????? ???????? ??????? ???????? ??
???? ?????? ???? ????????? ????? ???????.
????   : ????                          :
??? : ???????????? :
???  :                     ????????????????? :
????  : ???   :
? ???? ??????? ? ? ?? ?????? ??? ?????????
??????? ????????? ????? ???????.
? ??????? ????????? ????????????????????????
????????????????? ??.
? ???????????? ?? ??????????????????????????.
? ??? ??? ?? ????? ?????? ?????? ????? ??????
???????? ??????? ???????? ?? ???? ??????
???? ????????? ????? ??? ??????? ?
?????????????????? ?????????????????.
? ??????????? ??? ?? ??????????????????????
?????? ?????? ??????? ???? ????? ????? ??
????? ????? ???? ?????? ??????? ? ? ????
????????????????? ?? ?? .
??????? ???????????? ??????????????????
??????? ???? ???
??????? ?????: ??? ?? ????? ?????? ??????
????? ?????? ???????? ??????? ???????? ??
???? ?????? ???? ????????? ????? ???????.
????   : ????                          :
???  : ???????????? :
???    : ??????? ?????????   :
???  :
? ????? ???????????????????????????.
? ??? ?? ????? ?????? ?????? ????? ??????
? ???????? ??????? ???????? ?? ???? ??????
???? ????????? ????? ??? ??????? ???
??????????? ??.
? ?? ??? ??? ??????? ? ?????? ?????
?? ????? ??? ? ?? ??????? ? ??????? ???????? ??
???? ?? ?? ??? ?????????? ??????? ???
??????? ????????. ????? ????? ?????
????? ????? ???? ?? ? ????? ???? ??? ???????
??????? ????? ?? ?????? ???.
? ????????????????????????? ? ?????????????
??????? ? ? ??????? ?????? ????????? ????
?????????????? ???? ? ???????? ???????
????? ?? ?????? ???
? ???? ??????? ? ? ???????? ???????? ?? ?????
????? ???? ????? ?.???? ?? ??? ???????? ???
??????? ? ? ??? ?? ??????? ???????
????? ??????? ???.
? ?????? ?????????????? ??????????????? ? ?????
????? ??????? ? ? ???? ????? ??????
??? ???????????????????? ???????? ???.
??????? ???????????? ??????????????????

